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Abstract  
 
Cancer is one of the leading causes of death, worldwide. Mortality tolls are estimated 
to reach approximately 13.1 million in 2030. These statistics suggest that current 
therapeutic strategies are not effective. This is partly due to the fact that the drugs 
used in the treatment of cancer lack selectivity and specificity, which lead to 
undesirable side effects and reduced drug efficacy. There is therefore a need for 
alternative therapeutic approaches. In view of this, the therapeutic goal of 
chemotherapy has shifted towards targeted drug delivery systems, which have been 
successfully demonstrated using nanotechnology. The nano-based drug delivery 
vehicles that specifically target diseased cells are appealing as they could reduce drug 
toxicity towards healthy tissues and be more effective at lower dosages.  
The main aim of this study was to develop gold nanorods (AuNRs) capable of inducing 
cell death in cancer cells specifically. Selectivity of the AuNRs (denoted as AGK) for 
cancer cells was achieved by conjugating the AuNRs to a peptide (Adipose Homing 
Peptide or AHP) that has high affinity and specificity for a cell surface receptor 
(prohibitin or PHB) that is expressed on some cancer cells. Cell death was achieved 
through conjugating the AuNRs to a pro-apoptotic peptide, D(KLAKLAK)2. Spherical 
AuNPs (AuNSs) conjugated with AHP and D(KLAKLAK)2, capable of selectively inducing 
apoptosis in cancer cells that express PHB, was previously reported. However, in this 
study the AuNSs were replaced with AuNRs.  
AuNRs has the ability to absorb light in the near infrared (NIR) light spectrum and 
converts this light energy into heat. This property of AuNRs has been used in several 
studies to demonstrate the application of AuNRs for the treatment of cancer using 
photothermal therapy (PTT). Consequently, the AuNRs described in this study can 
also be used for PTT. These AuNRs can induce cell death through the target specific 
delivery of the pro-apoptotic peptide D(KLAKLAK)2 as well as through PTT. The study 
showed that three human cancer cell lines (PC-3, Caco-2 and U-87) express PHB. The 
cytotoxicity testing of AGK AuNPs on PC-3 cells showed that these AuNRs could 
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induce apoptosis in these cells without exposure to a NIR light source. The study also 
shows that AuNRs conjugated with the targeting peptide only (denoted as AG) can 
induce cell death in Caco-2 through PTT. This study demonstrates the potential of the 
AuNRs described in this study for application in the targeted elimination of cancer 
cells through the selective induction of PTT and apoptosis. 
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Chapter one: Literature review 
 
1.1.  Introduction 
 
Cancer is the second most common cause of death globally, exceeded only by 
ischaemic heart disease (American Cancer Society, 2016). According to World Health 
Organization (WHO), annual cancer cases are expected to rise from 14 million in 2012 
to 22 million within the next 20 years (World Health Organization, 2015) and surpass 
heart disease as the leading cause of death (Jemal et al., 2010). Cancer is a 
heterogeneous disease caused by both external and internal factors. External factors 
include infectious organisms, unhealthy diet, exposure to chemicals/radiation and 
tobacco. Internal factors include hormones, immune conditions and genetic 
mutations (İlem-Özdemir et al., 2015).  
 
Although conventional cancer therapies such as radiation, chemotherapy, 
immunotherapy and surgery have improved patients’ survival rate, mortality tolls are 
steadily escalating (Rivankar, 2014). The increased mortality can be largely attributed 
to drug non-specificity, resulting in inadequate targeting of the drugs to the tumour 
site as well as the resultant systemic side effects (Kumari et al., 2016). Further to non-
specific biodistribution, conventional anticancer drugs often have poor solubility, (Le 
Garrec et al., 2004). Minimal interaction between the drug and the tumour is thus 
associated with reduced drug efficacy (Kumari et al., 2016 & Arranja et al., 2017). 
Additionally, cancer cells are known to proliferate autonomously and uncontrollably, 
due to multiple mutations and acquisition of multidrug resistance (Sioud and 
Mobergslien, 2012 & Sims et al., 2016). There is therefore an urgent need to develop 
improved cancer therapeutics that can be disease-specific with higher efficacy.  
 
Nanotechnology-based systems were shown to have enhanced efficacy due to their 
ability to interact with diseased tissues at a cellular level with a great degree of 
specificity. These nanomedicines employ a strategy known as the enhanced 
permeability and retention (EPR) effect, which relies on porous vessels in the solid 
http://etd.uwc.ac.za/
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tumours (Steichen et al., 2013). These nanomaterials can be used as vehicles to 
transport therapeutic payloads to disease sites.  Nanoparticles can easily permeate 
and accumulate within the tumours via the EPR effect, leading to the sustained 
delivery of their therapeutic payloads (Yu et al., 2012 & Steichen et al., 2013). In this 
manner, toxicity could be limited to target cells, reducing side effects and immune 
response. This can significantly enhance the half-life of the therapy, mask the therapy 
from attack by phagocytes and reduce early drug clearance from the blood system. 
To develop the ideal nanotechnology-based cancer targeting system, an in-depth 
understanding of tumour pathophysiology, growth and mechanisms is required. 
Herein, prohibitin (PHB)-targeted nanorods are explored for their photothermal 
effect on cancer cells. 
 
 
1.2. Cancer development  
 
1.2.1. Tumour physiology 
 
Cancer can be described as a multi-gene and multi-step disease that originates from a 
single cell with unrepaired DNA damage (Hanahan and Weinberg, 2011). In the 
lifecycle of normal cells, signals dictate whether a cell will continue to divide, 
differentiate or die (Hejmadi, 2010). In contrast, during the development of cancer, 
cells with altered DNA acquire a degree of autonomy from these signals resulting in 
failure to repair or destroy such cells (Hanahan and Weinberg, 2011). As shown in 
Figure 1.1, the abnormal cells multiply and grow uncontrollably by escaping 
physiological functions such as apoptotic signalling (Hejmadi, 2010). The tumour 
microenvironment also plays a role in cancer development and progression; it 
promotes tumour growth through angiogenesis, which is the process of new blood 
vessel formation to sustain the growth of new tissue (Gupta and Zhang, 2005). From 
this perspective the growth of a tumour is new tissue requiring new blood vessel 
formation. As the tumour increases in size it develops into a dense population of cells 
with a poor drainage system. The tumour microenvironment is biochemically 
http://etd.uwc.ac.za/
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characterized by low levels of oxygen, low pH, and low glucose. Cancer cells are fast 
growing cells constantly requiring nutrients and oxygen in order to continue cell 
proliferation and gain metastatic potential (Rieger et al., 2016). Without new blood 
vessel formation, cancer cells will rely solely on diffusion of nutrients through the 
existing blood vessel network (Steichen et al., 2013). New blood vessel formation is 
therefore essential for the growth of the tumour.  
 
 
 
 
 
 
 
 
1.2.2. Tumour vasculature 
Like most cellular mechanisms, angiogenesis is regulated by the stimulation and 
blocking of cellular signals in a series of discrete steps during tumour development as 
indicated in Figure 1.2. Once the process is initiated, growing vessels produce a 
vasculature that is aberrant and unorganized (Haley and Frenkel, 2008). As a result, 
there are regions within the tumour that have high blood supply due to the presence 
of an extensive vasculature, while other regions, which are usually at the centre of a 
tumour mass, have low blood supply with poor vasculature (Byrne et al., 2008 & 
Danhier et al., 2010). Consequently, the delivery of anti-cancer drugs through the 
 
Figure 1.1: Tumour formation from a single cell. Failure to repair damaged DNA results in the 
malfunctioning of apoptosis. The abnormal cell grows and proliferates uncontrollably and undergoes 
successive rounds of mutation to form a tumour mass (www.thebraintumourcharity.org, 2016). 
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blood stream is not effectively delivered to the centre of the tumour (Betof et al., 
2015). Cancer cells proliferate much quicker than normal cells, resulting in abnormal 
basement membranes and incomplete endothelial linings and subsequently, leaky 
blood vessels (Haley and Frenkel, 2008 & Reiger et al., 2016). This gives rise to the 
EPR effect, which is a phenomenon exploited for delivery of conventional anti-cancer 
drugs (Steichen et al., 2013). It is speculated that the EPR effect facilitates the faster 
growth rate of cancer cells by allowing the passing of larger macromolecules such as 
bradykinin, nitric oxide / peroxynitrite, prostaglandins, vascular endothelial growth 
factor (VEGF), tumor necrosis factor (TNF) and others from the blood stream to the 
surrounding tumour tissue. It is also speculated that this promotes the delivery of 
anti-cancer drugs to the tumour since the drugs accumulate much faster in the 
tumour tissue compared to the normal tissues, which do not receive blood supply 
from leaky vessels. 
   
 
 
 
 
 
Figure 1.2: Signalling interactions during tumour growth. The tumour microenvironment is regulated 
by several signals of which only a few are illustrated. During angiogenesis tumour cells release factors 
such as VEGF which are pro-angiogenic. These factors then bind to and activate receptors present on 
existing blood vessels. Activated endothelial cells subsequently divide and migrate towards the 
tumour. A new basement membrane is formed by endothelial cells, which secrete growth factors 
such as Platelet-derived Growth Factor (PDGF) which stabilizes the new vessels by attracting 
pericytes. These pericytes form incomplete endothelial linings resulting in leaky vessels (Hanahan and 
Weinberg, 2011). 
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1.3. Current cancer therapies and their limitations 
 
Conventional cancer therapies include surgery, radiation, chemotherapy and 
immunotherapy. The course of treatment depends on the type of cancer, its location, 
and its state of advancement (Arranja et al., 2017). Surgery is one of the oldest forms 
of cancer therapy. It is, however, only feasible if the tumour is benign and has not 
metastasized (Durante and Loeffler, 2010). Furthermore, this form of therapy is 
relatively costly and more invasive and in many cases, the cancer can return. 
 
Radiation makes use of gamma rays, X-rays, or neutrons targeted directly to the 
tumour, causing the endothelial cells to swell and die (Li et al., 2003). Radiation is 
more harmful to cancerous cells than normal cells as they are unstable due to a faulty 
cellular repair mechanism and thus, more vulnerable to the damaging radiations 
(Mandal, 2013). At the beginning of the 20th century, shortly after the initial use of 
radiation, it was discovered that radiation could cause cancer as well as cure it due to 
the lack of selectivity towards cancer cells (Mandal, 2013). Martin et al. (2014) 
reported that the rapid breakdown of a tumour could cause a flood of cancerous cells 
to enter the lymphatic flow and form tumours in healthy organs, a possible 
mechanism of the formation of therapy-related metastasis. However, in patients with 
inoperable tumours, radiation therapy is one of the only options (Durante and 
Loeffler, 2010).  
 
Early in the 20th century, only tumours that were small and localized enough to be 
completely removed by surgery were curable. Radiation was used after surgery to 
control residual small tumour growth, this was often followed by chemotherapy to 
destroy small tumour growths that had spread beyond the reach of the surgeon and 
radiotherapist (Arranja et al., 2017).  A number of chemotherapeutic agents that are 
clinically used for cancer treatment are listed in Table 1.1, and these include 
anticancer drugs like Adriamycin, Paraplatin, Taxol etc. that are used to destroy 
cancer cells by inhibiting their cell division (Mandal, 2013 & Mauer et al., 2015). 
Nevertheless, chemotherapeutics have a short half-life, exert adverse side effects 
such as bone-marrow suppression, neuropathy, cardiotoxicity, hair loss and nausea; 
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have restricted drug dosage and cause systematic toxicities and multidrug resistance 
(Massey et al., 2014; Truong et al., 2014 & Arranja et al., 2017). Due to the non-
specificity of conventional therapies, tumour cells can continue their uncontrolled 
proliferation with consequent tumour recurrence and poor prognosis. In view of this, 
the therapeutic goal has shifted towards selective or targeted eradication of cancer 
cells whilst preserving healthy cells by using targeted drug delivery systems. In order 
to design such targeted delivery systems, drugs are incorporated into nanocarrier 
systems.  These systems are developed using nanotechnology (this will be discussed 
further in Section 1.8) which enable the design of multimodal systems that act as 
drug carriers, while simultaneously direct the delivery of the drugs to the tumour site. 
These delivery systems also have other advantages, most notably, increase of the 
circulation times of drugs (Kim et al., 2010; Chung et al., 2014 & Heinrich et al., 2016). 
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Chemotherapeutic 
agent 
Cancer type Possible short-term side 
effect 
Doxorubicin 
(Adriamycin) 
Breast cancer, 
lymphoma, and 
multiple myeloma 
Decrease in blood cell 
counts, mouth ulcers, hair 
loss (reversible), nausea 
and vomiting, and heart 
damage 
   
Carboplatin 
(Paraplatin) 
Ovarian, head and 
neck, and lungs 
Decrease in blood cell 
counts, hair loss 
(reversible), confusion, 
nausea, vomiting, 
diarrhoea 
   
Cisplatin (Platinol, 
Platinol-AQ) 
Bladder, Ovarian, 
and Testicular 
Decrease in blood cell 
counts, allergic reaction, 
including a rash and/or 
laboured breathing, 
nausea and vomiting that 
usually occurs for 24 hours 
or longer, ringing in ears 
and hearing loss, 
fluctuations in blood 
electrolytes, and kidney 
damage 
   
 Fluorouracil (5-FU) Colon, breast, 
stomach, and 
head and neck 
Decrease in blood cell 
counts, diarrhoea, mouth 
ulcers, photosensitivity, 
and dry skin. 
   
Paclitaxel (Taxol) Breast, ovarian, 
and lung 
Decrease in blood cell 
counts, allergic reaction, 
nausea and vomiting, loss 
of appetite, change in 
taste, thin or brittle hair, 
joint pain (short term), and 
numbness or tingling in 
fingers/toes 
 
 
 
 
Table 1.1: Conventional intravenously administered drugs and their side effects. 
 
(Adapted from Khan et al., 2014) 
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1.4. Targeted drug delivery systems for cancer treatment 
 
For the effective elimination of tumours, three essential dynamics should be 
considered: enhanced selectivity towards the target; capability of bypassing 
biological barriers; as well as selectively killing cancerous cells once it reaches the 
target (Cho et al., 2008). There are two modes of action that can be used for targeted 
drug delivery, passive and active targeting as depicted in Figure 1.3. 
 
 
 
 
 
 
 
Figure 1.3: Schematic of targeting drug delivery utilizing nanocarriers. (A) Passive targeting that 
shows the delivery of a nanocarrier containing an encapsulated drug to the tumour site. (B) Active 
targeting, which makes use of ligands attached to the nanocarrier which binds directly to receptors 
that are over expressed on tumour cells regardless of leaky vasculature (Kumari et al., 2016). 
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1.4.1. Passive targeting  
 
Passive targeting is the preferential accumulation of anti-cancer drugs at tumour sites 
and is dependent on the pathophysiology of the tumour mass as a whole and the 
uniqueness of the tumour microenvironment (Srinivasan et al., 2015).  The 
vasculature of tumours consists of leaky blood vessels, which supplies the growing 
mass of cells with nutrients and oxygen (de Barros et al., 2012). Due to decreased 
lymphatic drainage, the vessels become permeable to anti-cancer drugs and prevent 
them from leaving the tumour mass (EPR effect), resulting in elevated levels of intra-
tumour drug concentration and enhanced tumour cytotoxicity (Matsumura and 
Maeda, 1986 & Maeda et al., 2000). Neocarzinostatin (NCS) was the first anticancer 
protein to be conjugated to a polymer (styrene maleic acid copolymer SMA) to form a 
nanocarrier therapeutic, named SMANCS (Matsumura and Maeda, 1986). SMANCS 
had a longer circulation time than NCS. Later other anticancer drugs, which showed 
selective tumour accumulation in mice xenograft models were also developed (Kim et 
al., 2010; Chung et al., 2014 & Heinrich et al., 2016). Their circulating half-life ranged 
from hours to days in humans depending on the delivery system. The drug with the 
longest circulation half-life in humans (~300hrs) was shown to be dextran–
camptothecin and has also been shown to be less cytotoxic than the “free 
camptothecin drug” used in clinical phase II trials (Soepenberg et al., 2005). 
 
Although passive targeting appears efficient, specificity remains a challenge, as 
indicated by the delivery of the drug doxorubicin. The antineoplastic drug, 
doxorubicin is one of the first drugs that have been encapsulated into a nanocarrier. 
This led to the development of liposomal doxorubicin or Doxil, which makes use of 
the EPR effect to deliver doxorubicin to tumour tissues (Barenholz, 2012). Although 
Doxil has an extended circulation time and reduced cardiotoxicity when compared to 
free doxorubicin, increased toxicity was observed in other organs such as the skin and 
there was also no difference between Doxil and free doxorubicin in the amount of 
drug accumulation in the tumour tissue (Danhier, 2016). This suggests that the use of 
the EPR effect may not be a beneficial approach in all tumour types since the degree 
of cell membrane penetrability differs between tumour types and stage (Lammers et 
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al., 2007 & Hansen et al., 2015). To overcome this limitation, the use of targeting 
ligands as an alternative has been studied.  
 
 
1.4.2. Active targeting 
 
Active targeting makes use of agents that i) specifically recognize and target 
receptors that are (over-) expressed on cancer cells (transferrin, folate, Epidermal 
Growth Factor Receptor (EGFR) or Glycoprotein receptors) [Arranja et al., 2017] 
and/or ii) target the endothelial cells of tumour vasculature (VEGF, integrins or matrix 
metalloproteases) [Danhier, 2016]. Molecules or targeting moieties used to 
specifically bind to these receptors include antibodies (Davis et al., 2010), aptamers 
(Hrkach et al., 2012), small molecules such as folic acid (Park et al., 2016) and 
peptides (Aina et al., 2005). The targeting moieties selectively bind to tumour-specific 
antigens and then trigger receptor-mediated endocytosis for controlled release of 
payloads to the target cells (Ashley et al., 2011 & Lu et al., 2011). The drugs can 
diffuse from target sites and kill neighbouring tumour-associated cells (Chi et al., 
2017). These targeting systems show an increase in drug efficacy compared to 
passive targeting systems due to an improved target cell recognition and uptake 
rather than passive tumour accumulation (Lammers et al., 2012 & Danhier, 2016). As 
shown in Figure 1.4 active targeting can be achieved by using molecules such as 
antibodies, aptamers as well as ligands, which is discussed below.  
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1.4.2.1. Antibodies as cancer targeting agents 
 
As targeting agents, antibodies have high selectivity and binding affinity by virtue of 
the presence of two epitope binding sites in a single molecule (Yu et al., 2012). The 
first monoclonal antibody (mAb) able to specifically bind to tumour antigens was 
developed in 1975 (Köhler and Milstein, 1975), but the potential role of mAbs in 
cancer treatment was not explored until nearly two decades later (Béduneau et al., 
2007). The murine mAb Muromonab CD3 (OrthoClone OKT3®) was the first mAb to 
be approved by the FDA for clinical application (Thistlethwaite et al., 1984). Various 
cancers up regulate proteins such as surface antigens, including fetoprotein, human 
carcinoembryonic antigen, and human chorionic gonadotropin antigen, as well as 
Figure 1.4: Schematic showing methods used for active targeting of cancer cells. I) Antibody-based 
targeting, which involves the use of (A) monoclonal antibodies such as anti-Her2/neu antibody 
directed toward Her2/neu receptors on the target cell membrane and (B) antibody fragments: single-
chain variable fragments (scFV) such as single-chain anti-epidermal growth factor receptor (EGFR) 
antibody directed toward EGFR, or antigen-binding fragment (Fab) such as anti-Her2/neu Fab. II) 
Aptamer-based targeting such as the A10 RNA aptamer directed toward prostate-specific membrane 
antigen (PSMA) on the surface of the target cells. III) Ligand-based targeting such as (A) transferrin-
based targeting of nanoparticles toward transferrin receptors and (B) folate-based targeting using folic 
acid to target folate receptor alpha (FRα), which is upregulated on the surface of neoplastic cells 
(Bazak et al., 2015). 
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non-surface biomarkers which provide targets for mAb mediated targeting (Sultana 
et al., 2013). 
 
Human Epidermal growth factor Receptor 2 (HER2) cell surface receptor is 
overexpressed or mutated in a variety of solid tumours including breast (Wolff et al., 
2013), gastric (Liang et al., 2014), lung (Mazieres et al., 2013) and ovarian cancers (Cai 
et al., 2015). Treatment with trastuzumab, a humanized mouse mAb directed against 
HER2, has become the standard of care for HER2-overexpressing breast cancer 
(Hudis, 2007) and metastatic gastric cancer (Bang et al., 2010). The versatility and 
effectiveness of using mAb as a targeting moiety and therapeutic was demonstrated 
by delivering short interfering RNA (siRNA) to a solid tumour xenograft model of 
ovarian cancer using trastuzumab (Palanca-Wessels et al., 2016). Independent 
preclinical investigations and early phase clinical trials have shown the utility of mAb 
to deliver siRNA for the suppression of genes critical for tumour growth or resistance 
to chemotherapy (Davis et al., 2010 & Tabernero et al., 2013). These studies 
demonstrated the successful in vitro and in vivo mAb-targeted delivery of siRNA to 
HER2-overexpressing cancer cells with cleavage of target mRNA verified as the 
mechanism of gene suppression (Palanca-Wessels et al., 2016).  
 
Another novel putative therapeutic target is Delta-like protein 3 (DLL3) which play a 
role in high-grade neuroendocine carcinomas including Small-Cell Lung Cancer (SCLC) 
(Saunders et al., 2015 & Rudin et al., 2017). DLL3 is thought to inhibit the Notch 
receptor, which is a tumour suppressor (Chapman et al., 2010). A first-in-human, 
open-label, phase I study was conducted to deliver Rovalpituzumab tesirine, a DLL3-
targeted antibody-drug conjugate, and investigate the safety, tolerability, 
pharmacokinetics, and anti-tumour activity of rovalpituzumab tesirine in patients 
with SCLC or large-cell neuroendocrine tumours (Rudin et al., 2017). The study 
demonstrated encouraging anti-tumour activity with a manageable safety profile, 
suggesting that DLL3 is a clinically relevant, novel target for SCLC and that 
rovalpituzumab tesirine mAb-drug conjugate is selective for DLL3-positive SCLC 
(Rudin et al., 2017). Currently, there are several FDA approved mAb therapies with 74 
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approvals achieved between 19 January 2016 and 1 December 2017 alone (Food and 
Drug Administration, 2017).  Hundreds more are undergoing clinical trials. 
 
 
1.4.2.2. Aptamers as cancer targeting agents 
 
In oncology, another field that is rapidly expanding is the use of aptamers as targeting 
agents. Aptamers are short single-stranded DNA or RNA oligonucleotides that are 
folded into secondary and tertiary three-dimensional structures enabling specific 
binding to biological targets (Nichols and Bae, 2014). More than 900 aptamers have 
been generated from an iterative in vitro selective process called “systemic evolution 
of ligands by exponential enrichment” (SELEX), towards a wide range of targets such 
as inorganic ions, small organic ligands, amino-acids, nucleotides and derivatives, 
oligonucleotides, antibiotics, peptides, proteins, sugars, parasites, virus, cells and 
tissues (Lao et al., 2015). Aptamers are considered equivalent to mAbs based on their 
high sensitivity and specificity as targeting agents (Ni et al., 2011). Aptamers 
however, possess several advantages over mAbs such as their simple production 
methods, low production cost (Zhang et al., 2011) and they are more stable as they 
are resistant to bio degradation due to resistance to physical and environmental 
stressors such as heat, pH and organic solvents (Lee et al., 2010). They can be 
transported at ambient temperatures and remain stable during long-term storage 
(Talekar et al., 2011), exhibit slow degradation kinetics and can be denatured and 
renatured multiple times without significant loss of activity (Liss et al., 2002). Unlike 
mAbs they lack immunogenicity/toxicity (Zhang et al., 2011); and due to their small 
molecular weight (~10 -30 Da) they can penetrate tissues faster and more efficiently 
than a 150 kDa mAbs (Xiang et al., 2015).  
 
Farokhzad et al. (2004) first reported the use of the A10 RNA aptamers, which 
recognizes the extracellular domain of the Prostate-Specific Membrane Antigen 
(PSMA) for targeted drug delivery of nanoparticle/aptamer bioconjugates. In a follow 
up study, the authors showed that docetaxel encapsulated nanoparticles 
functionalised with the PSMA targeted RNA aptamer had significantly enhanced in 
vitro cytotoxicity compared to non-targeted nanoparticles (Farokhzad et al., 2006). In 
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a similar fashion, the PSMA aptamer-conjugated gold nanoparticles loaded with 
doxorubicin showed significantly more potent cytotoxicity against LnCaP cells than 
PC-3 cells, which do not express PSMA (Kim et al., 2010). More recently, an aptamer 
named NOX-A12, which neutralizes CXCL12 (a critical chemokine involved in the 
homing and retention of hematological cancer cells (Marasca and Maffei, 2014), was 
found to enhance the susceptibility of hematological cancer cells to conventional 
therapies, and inhibited the growth and metastasis of CXCL12-derived tumours 
(Hoellenriegel et al., 2014 & Liu et al., 2013). Clinical trials demonstrated that the 
combination of NOX-A12 and Bendamustine/Rituximab improved clinical responses 
in patients with chronic lymphocytic leukemia and multiple myeloma, as opposed to 
the single agents on its own (clinical trials IDs: NCT01486797 and NCT01521533) 
(Zhou et al., 2016).  
 
 
1.5. Cancer specific peptide ligands as targeting molecules 
 
1.5.1. Why peptides? 
 
The application of peptides as a targeting agent emerged to circumvent limitations 
presented by mAbs (Shadidi and Sioud, 2003). Peptides are typically differentiated 
from their larger counterparts (i.e. proteins) by having amino acid sequences less than 
50 residues (Bertrand et al., 2014). Although peptides are flexible and have lower 
affinity to receptors compared to mAbs, their use in theranostics (therapeutics and 
diagnostics) is advantageous due to their smaller size, reduced immunogenicity, high 
multivalency, deep tumour penetration, ease of synthesis and conjugation, and lower 
production costs (Cheng and Allen, 2010 & Bakhtiary et al., 2016). Peptides can be 
chemically modified to alter their affinity, charge, hydrophobicity, stability, and 
solubility allowing for fine-tuning of their in vivo bio-distribution (McGuire et al., 
2014). These advantages, combined with improved screening techniques to isolate 
ligand-substrate combinations have contributed to the increased role of peptides as 
targeting moieties in the past decade (Bertrand et al., 2014).  
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The importance of cancer cell surface receptors as therapeutic targets is exemplified 
by the successful use of mAbs such as Rituxan, Zevalin, Herceptin, and Mylotarg in 
the treatment of cancer (Aina et al., 2005). Peptides are believed to be better cell 
surface–targeting agents than mAbs, particularly when used as carriers and targeting 
moieties for cytotoxic payloads such as chemotherapy or radionuclides (atoms that 
have excess nuclear energy) (Aina et al., 2005). Cancer targeting peptides can be 
identified using Phage display technology (Arap et al., 1998). Phage display is an in 
vitro screening technique, which makes use of bacteriophages to study 
protein/protein (Beirnaert et al., 2017), protein/peptide (Wu et al., 2016), and 
protein/DNA interactions (Godonoga et al., 2016). Phage display has been used 
successfully to identify several cancer targeting peptides (Che et al., 2015 & Lee et al., 
2016).  
 
 
1.5.2. Known cancer targeting peptides 
 
Two peptides with the following sequences; WSGPGVWGASVK (Ma et al., 2013) and 
SVSVGMKPSPRP (Zhang et al., 2011) were identified to have high affinity for the 
ovarian cancer cell line (SKOV-3). However cancer is a heterogeneous disease, and 
there are various pathological types of ovarian cancer, and not one peptide can be 
used for all cell types, an indication of specificity. A novel peptide (with the following 
sequences NPMIRRQ) was shown to target HO-8910 ovarian cancer cells (Wang et al., 
2016). Eleven peptides were isolated using three phage display peptide libraries on a 
series of well-defined human Non-Small Cell Lung Cancer (NSCLC) cell lines (McGuire 
et al., 2014). The peptides showed distinct binding profiles across 40 NSCLC cell lines 
and did not bind normal bronchial epithelial cell lines. Furthermore, both in vivo and 
ex vivo studies demonstrated that the peptides home to tumours (McGuire et al., 
2014). These peptides add to the growing toolbox of tumour targeting agents and 
their versatility allows for easy incorporation into a variety of imaging and drug 
delivery systems. 
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In a recent study, a 12 amino acid trastuzumab-mimetic peptide, named anti-
HER2/neu peptide (AHNP) was used to deliver a pro-drug called poly (β-L malic acid) 
(PMLA) to HER2 + cells using a polymeric nanoparticle (Ding et al., 2017). The authors 
demonstrated that HER2+ cells were inhibited by the nanodrug, which prevented 
cancer cell proliferation and significantly reduced the tumour size. A protein that 
plays a vital role in prostate cancer is Wiskott-Aldrich syndrome protein Family 
member 3 (WASF3) [Teng et al., 2010]. Its inactivation leads to suppression of 
invasion and metastasis regardless of the genetic background of the cancer cell. 
WASF3 in combination with a series of other proteins make up the WASF Regulatory 
Complex (WRC). A series of stapled peptides that disrupt protein-protein interactions 
between members of the WRC was developed (Teng et al., 2016).  These peptides are 
capable of suppressing invasion. Stapled peptides are constrained into an alpha-
helical formation, which increases proteolytic stability, active uptake into cancer cells, 
and higher specificity for the intended target due to the large interacting interface 
(Guerlavais and Sawyer, 2014). The authors developed a stapled peptide that 
mimicked an alpha-helical interaction between WASF3 and CYFIP1 (a protein that 
maintains stability of WRC). This peptide suppressed WASF3 phospho-activation and 
led to the suppression of invasion in breast and prostate cancer cells (Teng et al., 
2016). Cowell et al. (2017) demonstrated that stapled peptides targeting protein-
protein interactions that are essential for the maintenance of the WRC can supress 
lung and liver metastasis in vivo. 
 
Although tumour targeting peptides enable the internalization of drugs, certain drugs 
once internalized, are unable to localise to the mitochondria on their own in order to 
initiate the apoptotic process. CGKRK is a well-known tumour homing peptide, 
discovered by phage display technique (Hoffman et al., 2003). It mediates the cellular 
internalization in a p32 receptor-dependent manner, then it localizes to mitochondria 
in cells (Agemy et al., 2013). This cancer targeting peptide has been used to deliver 
the pro-apoptotic peptide (D(KLAKLAK)2) to cancer cells. This pro-apoptotic peptide is a 
cationic α-helical amphipathic peptide (Javadpour et al., 1996). This peptide was 
previously shown to have antimicrobial activity by damaging the bacterial cell membrane, 
but was unable to cross the Eukaryotic plasma membrane (Javadpour et al., 1996). To 
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exploit its cytotoxic activity in the treatment of cancer, the D(KLAKLAK)2 peptide has been 
coupled to cancer targeting peptides (Ellerby et al., 1999).  
 
Mozhi et al. (2017) used the CGKRKD(-KLAKLAK)2 fusion peptide to produce pH sensitive 
polymeric micelle nanoparticles, which also encapsulated the anti-tumour drug docetaxel 
(Figure 1.5). The mitochondria protein, p32 that is the target for CGKRK, is overexpressed 
on the surface of various cancer cells (Agemy et al., 2013). The CGKRK peptide facilitates 
the docking of the micelle nanoparticles to cancer cells. Once internalized, the fusion 
peptide and docetaxel is released via pH sensitive trigger. Docetaxel exert its anti-tumour 
activity by promoting polymerization of tubules by binding to beta-tubulin and locking the 
structures in place (Apfel, 1996). The fusion peptide is targeted to the mitochondria via 
the CGKRK peptide, while the D(KLAKLAK)2 peptide triggers mitochondria-dependent 
apoptosis (Figure 1.5). The cationic D(KLAKLAK)2 amino acids only disrupt the 
mitochondrial membrane once they are attached to the head groups of anionic 
phospholipids in the mitochondrial membrane. The peptide preferentially disrupts the 
mitochondrial membrane because of their higher anionic phospholipid content than the 
zwitterionic phospholipids of the cytoplasmic membranes. Thus D(KLAKLAK)2  has minimal 
toxicity outside of the mammalian cell and only induces mitochondria-dependent 
apoptosis once internalized (Wang and Huang, 2012). The combination of docetaxel and 
the therapeutic D(KLAKLAK)2 peptide displayed a synergistic anti-tumour effect in an MCF-
7 cell line. The therapeutic mechanism of action of the CGKRK and D(KLAKLAK)2 bi-
conjugate to deliver docetaxel is shown in Figure 1.5 (Mozhi et al., 2017). 
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1.6. Prohibitin as the ideal target for peptides 
 
The prohibitin (PHB) gene was originally isolated and characterized in rat liver cells 
(McClung et al., 1989) and maps to chromosome 17q21-21 (Sato et al., 1993). PHB 
belongs to a family of proteins called Band-7, is highly conserved evolutionarily and is 
ubiquitously expressed in various compartments of eukaryotic cells which include the 
mitochondria, nucleus, and plasma membrane as shown in Figure 1.6. PHB located in 
different cellular compartments function in different biological processes, which are 
involved in multiple diseases such as obesity and cancer.   
 
Figure 1.5: Schematic of the drug-loaded polymeric micelles and their cellular uptake mechanism. 
Delivery of docetaxel and the therapeutic peptide by targeted micelles from the blood circulation into 
the tumour tissue and internalization of the targeted micelles by tumour cells via a receptor-mediated 
endocytosis pathway (Mozhi et al., 2017). 
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Kolonin et al. (2004) used phage display technology to identify a peptide (with amino 
acid sequence: CKGGRAKDC) that bind to the vasculature of obese tissue. PHB, which 
is over expressed in the endothelial cells (ECs) of the vasculature of the white adipose 
tissue (WAT), was identified as the target for this peptide. Consequently the peptide 
was named Adipose Homing peptide (AHP). Kolonin et al. (2004) also demonstrated 
that when AHP was coupled to the pro-apoptotic peptide D(KLAKLAK)2, it could be 
used to reverse obesity in mice. The study showed that when the fusion peptide was 
injected into obese mice, the AHP-conjugate was internalized and localized by the 
blood vessels of the subcutaneous and peripheral white fat, but not other organs. 
This led to the death of vascular ECs by apoptosis, subsequent resorption of fat in the 
WAT, normalization of metabolic processes and weight loss. Due to the specificity of 
AHP, no systemic or bystander effects were observed. The desired effect of 
treatment was dependent on the internalization of treatment through the interaction 
Figure 1.6:  The subcellular localization of prohibitin and potential cellular processes PHB is involved 
in. PHB is present on the cell membrane where it can interact with various targeting ligands. Such 
ligands could potentially translocate to the mitochondria and disrupt mitochondrial function, resulting 
in apoptosis. PHB might also translocate from the cell membrane to the nuclear compartment where 
it might function as a modulator of transcription. The phosphorylation of PHB, possibly by the JNK1 
pathway, might be necessary for the anti-proliferative effects of PHB. The latter involves the 
interaction with Brg–Brm, inhibition of the E2F pathway and both p53- and pRB-dependent and p53- 
and pRB-independent mechanisms (Mishra et al., 2005).  
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between the PHB and the AHP-complex (Kolonin et al., 2004). On binding to the PHB 
receptor, the AHP-conjugate gets internalized and released inside the cell and the 
PHB receptor is then recycled and available for the next cycle, provided the cell is still 
alive (Kolonin et al., 2004).  
 
Several studies using different model organisms suggest that PHB not only plays a 
role in obesity but in cancer as well. Data from The Cancer Genome Atlas (TCGA) and 
The Human Protein Atlas (THPA) show that PHB is widely expressed in diverse 
cancers, at both mRNA and protein levels (Uhlen et al., 2017). PHB expression levels 
are significantly correlated with tumour metastasis and poor prognosis according to 
literature (Chang et al., 2010; Liao et al., 2013; Cao et al., 2016 & Küçük et al., 2016). 
In many cancers, the Raf/ERK signalling pathway is constitutively activated, 
promoting cancer cell metastasis. For example, HeLa cells showed that 
phosphorylation of PHB in lipid rafts of the plasma membrane is necessary for the 
activation of Raf/ERK signalling cascades supporting cancer cell metastasis (Chiu et 
al., 2013). A similar mechanism was observed in pancreatic ductal adenocarcinoma 
(Luan et al., 2014) and gall bladder cancer as well (Cao et al., 2016). In addition to the 
Raf ⁄ERK signalling pathway, PHB is implicated in the TGF-β (Ghazy et al., 2017) as 
well as the PI3K ⁄ Akt signalling pathways (Dong et al., 2016), which involves the 
phosphorylation of PHB. All these signalling pathways are involved in cancer and PHB 
is thus an ideal target for ligands such as AHP to interfere in these signalling pathways 
with the aim of inhibiting cell proliferation and cancer development by inducing 
apoptosis.  
 
Similarly and of interest to this study, Sibuyi et al. (2017) reported on an in vitro anti-
proliferative activity of PHB-targeted gold nanoparticles (AuNPs) that used D(KLAKLAK)2  to 
induce apoptosis. The targeted nanotherapy was developed by bi-functionalizing spherical 
AuNPs with the targeting peptide (AHP) and the pro-apoptotic peptide (D(KLAKLAK)2 ). 
Previous studies showed that Caco-2 cells express PHB on the cell surface (Nijtmans et 
al., 2000; Sharma and Qadri, 2004 & Thovhogi et al., 2015), while the breast cancer cell 
line, MCF-7, most likely express PHB in the cytoplasm (Rastogi et al., 2006). Caco-2 cells 
are therefore excellent in vitro cell culture models to test the specificity of PHB-targeted 
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AuNPs. Thovhogi et al. (2015) also showed the specific binding of AHP–FITC to Caco-2 cells 
using competitive binding assays. As further corroboration of this, Sibuyi et al. (2017) 
showed that AHP–FITC is able to bind to Caco-2 cells, but not to the breast cancer cell line 
MCF-7. This confirms that Caco-2 cells express PHB, the receptor for AHP on the cell 
surface, while MCF-7 cells do not. The PHB-targeted AuNPs were highly toxic to Caco-2 
cells resulting in the induction of apoptosis within these cells, while leaving the viability of 
MCF-7 cells unaffected. These results demonstrate that the AuNPs specifically only kills 
cells that express PHB, the receptor for AHP on the cell surface and that the toxicity is 
likely to be caused by the pro-apoptotic peptide D(KLAKLAK)2. This study demonstrates the 
efficacy and specificity of PHB-targeted nanotherapy in vitro, and provides the proof of 
principle for PHB-targeted therapy. 
 
 
1.7. The role of apoptosis in cancer progression 
 
Apoptosis, a highly organized and regulated process, is the most investigated and 
best understood mechanism of programmed cell death (Su et al., 2013). It functions 
as a defence mechanism against cytotoxic agents in order to maintain homeostasis 
within cell populations (Su et al., 2013). Apoptosis can be distinguished from necrosis 
(traumatic cell injury that is fatal to the surrounding tissue of the target cell) by its 
unique morphological and biochemical alterations (Rønning et al., 2017) as shown in 
Table 1.2.  
 
 
 
 
Apoptosis Necrosis 
Occurs in single cells or small clusters of 
cells 
Often contiguous cells 
Cell shrinkage and convolution Cell swelling 
Pyknosis and karyorrhexis Karyolysis, pyknosis, and karyorrhexis 
Intact cell membrane Disrupted cell membrane 
Cytoplasm retained in apoptotic bodies Cytoplasm released 
No inflammation Inflammation usually present 
 
Table 1.2: Morphological features of apoptosis and necrosis  
 
(Human Protein Reference Database http://www.hprd.org/). 
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Apoptosis is triggered by a variety of cellular signals which include DNA replication 
stress (Gorgoulis et al., 2005; Hills and Diffley, 2014 & Desmarais et al., 2016), 
violation of cell-cycle checkpoints (Castedo et al., 2004 & Vaish et al., 2014), 
increased intracellular Ca2+ concentration (Sergeev and Song, 2014), hypoxia (Shimizu 
et al., 1996 & Liu et al., 2013) as well as oxidative damage caused by reactive oxygen 
species (ROS) [Annunziato et al., 2003; Valko et al., 2006 & Lu et al., 2014]. The 
evasion of apoptosis (Figure 1.7) is one of the six hallmarks of cancer (Hanahan and 
Weinberg, 2000), underscoring the important role of this pathway in survival of 
malignant cells.  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7: The six hallmarks of cancer. The variety of cancer cell genotypes is a manifestation of six 
essential alterations in cell physiology that collectively dictate malignant growth: self-sufficiency in 
growth signals, insensitivity to growth-inhibitory (antigrowth) signals, evasion of apoptosis, limitless 
replicative potential, sustained angiogenesis, and tissue invasion and metastasis (Hanahan and 
Weinberg, 2000). 
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1.7.1. Apoptotic pathways 
 
Two different apoptosis pathways have been identified: the intrinsic/mitochondrial 
pathway and the extrinsic/physiological pathway (Figure 1.8) [Hengartner, 2000]. 
There is an overlap between these pathways as the extrinsic pathway can also 
activate the intrinsic pathway. Both pathways result in the recruitment and activation 
of cysteine-aspartic acid proteases (caspases) [Miura et al., 1993 & Yuan et al., 1993]. 
Once caspases are activated, there seems to be an irreversible commitment towards 
cell death (Elmore, 2007).  
 
 
 
 
 
 
 
 
 
 
Figure 1.8: The intrinsic and extrinsic apoptotic pathways. In the extrinsic apoptotic pathway is 
activated by death receptors that recruit death ligands such as tumour necrosis factor (TNF)-related 
apoptosis-inducing ligand (TRAIL) receptor (TRAILR) and FAS which can activate initiator caspases 
(caspase-8 and caspase-10), leading to apoptosis. The intrinsic (or mitochondrial) pathway is activated 
in response to cellular stress and requires mitochondrial outer membrane permeabilization (MOMP), 
resulting in the release of pro-apoptotic proteins from the mitochondria such as second mitochondria-
derived activator of caspases (SMAC) and cytochrome c, which activate downstream caspases (Ichim 
and Tait, 2016). 
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1.7.1.1. The extrinsic pathway 
 
The extrinsic pathway involves transmembrane receptor-mediated interactions 
(Locksley et al., 2001). It is activated upon binding and activation of plasma 
membrane cell death receptors (e.g. apoptosis stimulating factor [Fas], tumour 
necrosis factor receptor [TNFR], and TNF-related apoptosis-inducing ligand [Trail]) by 
their specific ligands (Ashkenazi and Dixit, 1998). These death receptors share similar 
cysteine-rich extracellular domains and have a cytoplasmic domain of about 80 amino 
acids called the “death domain”. This death domain plays a critical role in 
transmitting the death signal from the cell surface to the intracellular signalling 
pathways (Elmore, 2007).  
 
The series of events that define the extrinsic pathway of apoptosis are best 
characterized with the FasL/FasR and TNF-α/TNFR1 models (Ashkenazi and Dixit, 
1998). In these models, receptors cluster and bind with their homologous trimeric 
ligands. Upon ligand binding, cytoplasmic adapter proteins are recruited which 
exhibit corresponding death domains that bind to the receptors. The binding of the 
Fas ligand (FasL) to the Fas receptor (FasR) results in trimerization to produce a 
death-inducing signalling complex (DISC) which includes the Fas-associated protein 
with death domain (FADD), resulting in the cleavage of effector caspases (caspase-3, -
6 and -7) [Peter and Krammer, 2003]. The D-type cyclins (D1, D2 and D3) in the 
mammalian cell cycle machinery drives cell proliferation, and repress FasL/FasR 
expression (Choi et al., 2014). Thus, the over-expression of D-type cyclins plays a 
causative role in the development of many cancers (Beroukhim et al., 2010).  
Ablation of all three D-cyclins in the bone marrow of adult mice led to apoptosis via 
the FasL/FasR pathway (Choi et al., 2014).  
 
The binding of the TNF ligand to the TNF receptor results in the binding of the 
adapter protein, Tumour necrosis factor receptor type 1-associated DEATH domain 
protein (TRADD) with recruitment of FADD and Receptor-interacting protein (RIP) 
[Tartaglia et al., 1993]. FADD then associates with procaspase-8 via dimerization of 
the death effector domain (Smith et al., 1994). At this point, DISC is formed, resulting 
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in the auto-catalytic activation of pro-caspase-8. Once caspase-8 is activated, the 
execution phase of apoptosis is triggered (Ashkenazi and Dixit, 1998). Death receptor 
mediated apoptosis can be inhibited by a protein called cellular FLICE-inhibitory 
protein (c-FLIP), which binds to FADD and caspase-8, rendering them ineffective 
(Kataoka et al., 1998). The TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) 
induces apoptosis in cancer cells by binding to two transmembrane agonistic 
receptors, DR4 (TRAIL-R1) and DR5 (TRAIL-R2). Even though TRAIL has shown efficacy 
in a phase II clinical trial of patients with relapsed/refractory non-hodgkin’s 
lymphoma (Goy et al., 2005), resistance by several cancers is a major setback. The 
anti-cancer drug, Azadirone can sensitize cancer cells to TRAIL–induced apoptosis in 
order to overcome resistance to TRIAL. Azadirone does this by up regulating DR4 and 
DR5 receptors, downregulating cell survival proteins, and upregulating pro-apoptotic 
proteins. Thus combinations of azadirone and TRAIL are an effective approach for 
cancer therapy (Gupta et al., 2013).   
 
 
1.7.1.2. The Intrinsic pathway 
 
The Intrinsic/mitochondrial pathway is initiated by a range of exogenous and 
endogenous stimuli such as oxidative stress, DNA damage and ischemia (inadequate 
blood supply to tissues/organs) (Elmore, 2007). It plays an important role in 
development and elimination of damaged cells (Muñoz-Pinedo, 2012). The pathway 
is regulated by the Bcl-2 (B-cell lymphoma 2) family which consists of pro- and anti- 
apoptotic regulatory proteins, such as Bax (bcl-2-associated X) and Bcl-2, respectively 
(Caltabiano et al., 2013). The functional consequence of pro-apoptotic signalling is 
the opening of the mitochondrial permeability transition (MPT) pore, loss of the 
mitochondrial transmembrane potential and release of two main groups of pro-
apoptotic proteins normally sequestered from the intermembrane space into the 
cytosol (Saelens et al., 2004). The first group consists of cytochrome c, Smac/DIABLO, 
and the serine protease HtrA2/Omi (Garrido et al., 2006). Cytochrome c binds and 
activates Apaf-1 as well as pro-caspase-9, forming an “apoptosome” (Hill et al., 2004). 
The apoptosome hydrolyzes adenosine triphosphate (ATP) to cleave and activate 
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caspase-9. The initiator caspase-9 then cleaves and activates executioner caspases-3, 
-6, and -7, resulting in apoptosis (Loreto et al., 2011).  
 
The anti-apoptotic proteins, bcl-2 and bcl-xL inhibit the release of Cytochrome c 
(Fesik, 2000).  The second group of pro-apoptotic proteins, AIF (Apoptosis- inducing 
factor), endonuclease G and CAD (carbamoyl-phosphate synthetase 2, aspartate 
transcarbamylase, and dihydroorotase) are released from the mitochondria during 
apoptosis, but this is a late event that occurs after the cell has committed to die 
(Elmore, 2007). AIF and endonuclease G both translocate to the nucleus and causes 
DNA fragmentation in a caspase-independent manner (Li et al., 2001). CAD is 
subsequently released from the mitochondria and translocates to the nucleus where, 
after cleavage by caspase-3, it leads to oligonucleosomal DNA fragmentation and a 
more pronounced and advanced chromatin condensation.  
 
 
1.7.2. Pro-apoptotic agents as anti-cancer drugs 
 
Apoptosis is a complex process with numerous points of regulation, which could be 
manipulated for therapeutic benefit for the treatment of cancer. A greater 
understanding of these regulatory pathways and how they are altered in cancer 
resulting in resistance to apoptosis has been key in the development of pro-apoptotic 
agents. Interestingly, mutation rates in apoptotic proteins such as death receptors 
(Lee et al., 2001) or Bcl-2 proteins (Kim et al., 2012) are low, indicating that many 
cancer cells have apoptotic machinery, but they are being inhibited. If the machinery 
were to be unblocked, it would efficiently kill tumour cells (Fox and MacFarlane, 
2016). The three key points in apoptotic signalling pathways often targeted to 
overcome the resistance of apoptosis in cancer are discussed below. 
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1.7.2.1. Current pro-apoptotic molecules used in therapy  
 
Three key points in apoptotic signalling pathways are used as targets for cancer 
therapeutic strategies. One of which is triggering extrinsic apoptosis via death 
receptors by the addition of exogenous ligands such as TRAIL, which will initiate DISC 
formation and cause cell death by apoptosis (Fox and MacFarlane, 2016). TRAIL is a 
robust and selective tumour suppressor that offers itself as an attractive natural drug 
target to restore anti-tumour immunity. The TRAIL-inducing compound 
ONC201/TIC10 induced sustained TRAIL up-regulation and apoptosis in tumour cells 
in vitro and in vivo experiments while sparing normal cells (Allen et al., 2015). 
ONC201/TIC10 exclusively activates Foxo3a transcription factor (Ghaffari et al., 2003) 
through inactivation of the Akt/ERK pathway, which results in up-regulation of TRAIL 
and its pro-apoptotic death receptor DR5 (Allen et al., 2015). Another novel class of 
small molecules named bioymifi are capable of activating the TRAIL death receptor 
pathway by specifically binding and activating the death receptor DR5, inducing DR5 
clustering and aggregation, leading to apoptosis (Wang et al., 2013). Although TRAIL 
can induce apoptosis in several cancer cell lines, it has emerged that most primary 
cancer cells are resistant to TRAIL monotherapy (Lemke et al., 2014). 
 
The second apoptotic signalling pathway that is a target for therapeutic intervention 
is to initiate apoptosis by targeting anti-apoptotic Bcl-2 family members mainly BCL-2, 
Bcl-xL and MCL-1 (Fox and MacFarlane, 2016) as well as pro-apoptotic effectors (Bax 
and Bak) (Korsmeyer, 1992). ABT-737 and its analogue ABT-263 (Navitoclax) bind to 
and inhibit Bcl-2, Bcl-xL and Bcl-W, but not MCL-1 (Anderson et al., 2014). They were 
the first inhibitors of anti-apoptotic Bcl-2 proteins to be identified. Although 
Navitoclax showed promising clinical activity, it also induced thrombocytopenia (a 
condition characterized by abnormally low levels of platelets in blood) as a result of 
Bcl-xL inhibition (Rudin et al., 2012). ABT-199 (Venetoclax) has similar Bcl-2 inhibitory 
activity as Navitoclax’s, but does not have toxicity towards platelets (Souers et al., 
2013). ABT-199 has recently been approved by the FDA for the treatment of chronic 
lymphocytic leukaemia patients with an overall response rate of 79% (Roberts et al., 
2016). A common drug resistance mechanism in cancer cells, which is caused by 
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elevated MCL-1 expression has been identified for both ABT-263 and ABT-737 (Yecies 
et al., 2010). In a recent study, doxorubicin and dinaciclib showed synergistic effect 
with ABT-263 through the downregulation of MCL-1, thereby enhancing the pro-
apoptotic effect of ABT-737/263 in SCLC (Inoue-Yamauchi et al., 2017). Furthermore, 
combinations of the Bcl-2 inhibitor ABT-199 and either doxorubicin or dinaciclib 
provided effective therapeutic strategies in mouse xenograft cancer models, 
validating new potential therapeutic strategies for SCLC. 
 
The third key point involves targeting regulatory pathways, either by increasing 
caspase activity or inhibiting the inhibitor of apoptosis proteins (IAPs) using 
compounds that mimic the endogenous IAP antagonist, SMAC (Fox and MacFarlane, 
2016).  IAPs are a highly conserved family of signalling regulators that play key roles 
in the promotion of survival signalling (Walczak, 2011). SMAC is an endogenous 
antagonist of IAPs, it is released from the mitochondria in response to apoptotic 
stimuli and neutralizes IAPs thus allowing sustained caspase activity and execution of 
the apoptotic process (Fulda and Vucic, 2012). Smac mimetics have been designed to 
overcome IAP-mediated apoptosis resistance of cancer cells. Birinapant (TL32711), a 
bivalent SMAC-mimetic compound activates caspase-8 by binding to the BIR3 
domains of IAPs 1 and 2 (cIAP1 and cIAP2), x-linked IAP (XIAP), and the Baculovirus 
IAP Repeat (BIR) domain of Melanoma-IAP (ML-IAP) in vitro to induce apoptosis. 
Moreover, birinapant displayed antitumor activity at well-tolerated doses in murine 
xenograft models of ovarian and colorectal cancers and melanoma patient–derived 
tumours. This data suggests that birinapant targets IAP proteins to trigger an 
apoptotic response both in vitro and in vivo and has potential application in multiple 
tumour malignancies (Benetatos et al., 2014). Smac mimetics have demonstrated 
synergy with other treatment, including cytotoxic agents such as carboplatin (Janzen 
et al., 2015), paclitaxel (Yang et al., 2016) and radiation therapy (Matzinger et al., 
2015). Although these synergies are well defined in pre-clinical models, so far they 
have been less successful in clinical settings (Parton et al., 2015; Noonan et al., 2016 
& Finlay et al., 2017).  
 
http://etd.uwc.ac.za/
29 
 
1.8. Nanotechnology based drug delivery systems 
 
1.8.1. Nanotechnology 
 
Emerging nanotechnology-based therapeutics are providing solutions to the 
shortcomings of conventional cancer treatments (Danhier, 2016). Nanotechnology 
refers to the fabrication, characterization and applications of active substances in 
nanometer scale dimension (~1-100nm) for various applications (Sridhar et al., 2015). 
The ideal nanotechnology-based drug delivery system for biological application 
should possess certain characteristics, such as: chemical compatibility (Di Martino et 
al., 2017), selective toxicity (Korrapati et al. 2016), biodegradability and 
biocompatibility (Gagliardi et al., 2017), be easy to design and modify (Richards et al., 
2017), preferably synthesised from natural/biological materials (Korrapati et al. 
2016), and have an increased drug loading capacity (Gupta et al., 2017). 
 
 
1.8.2. Nanomaterials used for drug delivery 
 
In the last decade, advances in nanotechnology-based drug delivery systems have 
enabled more effective drug design and development, which has revolutionized 
conventional cancer therapies (Kanamala et al., 2016). According to Wicki et al. 
(2015), a total of 1381 nanomedicines for cancer treatment were registered for 
clinical trials by December 2014; these include liposomes, polymer-drug conjugates, 
micelles, carbon nanoparticles and metallic nanoparticles (illustrated in Figure 1.9).  
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1.8.3. Gold nanoparticles (AuNPs) 
 
One of the most widely studied nanoparticles (NPs) are gold nanoparticles (AuNPs). 
AuNPs are used as drug carriers, photothermal agents, radiosensitizers, contrast 
agents and have also shown promise for cancer therapy. There are various types of 
AuNPs as shown in Figure 1.10 such as gold−silica nanoshells, nanorods, nanocages 
and nanostars. 
 
 
 
 
 
 
 
Figure 1.9: Commonly utilized nanomaterials for biomedical applications. (A) Liposomes, (B) 
Polymer Conjugate, (C) Micelles, (D) Dendrimers, (E) Carbon nanoparticles and (F) Inorganic (gold) 
nanoparticles (Kumari et al., 2016). 
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1.8.3.1. Application of AuNPs in targeted drug delivery 
 
The customizable size, shape, and diverse physicochemical properties of AuNPs as 
well as their potential for surface functionalization with drugs or other molecules, 
make AuNPs promising tools as drug carriers to disease sites (Niikura et al., 2013 & 
Paul et al., 2014). As previously stated, the targeted drug delivery approach could be 
an alternative to conventional therapy, which will reduce the detrimental side effects 
caused by off-target drug delivery and high drug doses (Tomuleasa et al., 2012). 
Hepatocellular carcinoma-derived tumour cells treated with AuNP-drug conjugates 
showed significantly lower cellular proliferation than cells treated with the free drugs 
alone, supporting surface-functionalised AuNPs as an efficient targeted delivery tool 
for the treatment of cancer (Tomuleasa et al., 2012). The penetration of the blood–
brain barrier is a significant problem in the treatment of brain tumours. Ruan et al. 
(2015) demonstrated that functionalised AuNPs loaded with the anti-tumour drug, 
doxorubicin can target glioma cells in a mouse cancer model. In the study by Ruan et 
al. (2017) the AuNPs were functionalised with angiopep-2, a specific ligand of low-
density lipoprotein receptor-related protein-1, which could mediate transfer across 
the blood–brain barrier. The advantage of this treatment was that doxorubicin could 
be delivered across the blood brain barrier to glioma cells (Ruan et al., 2015).  
 
A B C D
Figure 1.10: Schematic and Scanning Electron Microscopy (SEM) images of AuNPs. Four of the most 
commonly employed AuNPs include A) silica core/gold shell nanoshells, B) gold nanorods, C) hollow 
gold nanocages, and D) nanostars. (Riley and Day, 2017). 
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Various approaches have been used to develop cancer therapies using AuNPs, some 
of which are currently undergoing clinical trials. In this regard, Li et al. (2016) showed 
that the clinically tested CYT-6091 nanodrug, which is a novel AuNP conjugated to 
recombinant human tumour necrosis factor (rhTNF) (Libutti et al., 2010), may be 
administered systemically at doses of “free rhTNF” that were previously shown to be 
toxic. However, although a wide variety of NP treatments have proven to be very 
successful in clinical trials, only a few nanomedicines, such as Doxil® (Janssen Biotech 
Inc., Horsham, PA, USA), Myocet® (Sopherion Therapeutics Inc., Princeton, NJ, USA), 
DaunoXome® (Galen US Inc., Souderton, PA, USA), Depocyt® (Pacira Pharmaceuticals 
Inc., San Diego, CA, USA), Abraxane® (Celgene Corporation, Inc.,Berkeley Heights, NJ, 
USA), Genexol-PM® (Samyang Biopharmaceuticals Corporation, Jongno-gu, Seoul, 
Korea), and Oncaspar® (Enzon Pharmaceuticals Inc., Bridgewater, NJ, USA), are FDA 
approved for use in the treatment of cancer, none of which consist of AuNPs, 
indicating a formidable “bottle neck” in translating research from bench to bed-side 
(Sanna et al., 2014). This could be due to the fact that although AuNPs are inert and 
biocompatible, contradictory results have been obtained regarding their toxicity 
towards cells. 
 
 
1.8.3.2. Cytotoxicity of AuNPs 
 
Different AuNP synthesis methods produce AuNPs with different characteristics. The 
cytotoxicity of the NPs is a common measure for the biocompatibility of materials 
(Favi et al., 2015). The cytotoxicity of AuNPs is directly related to the following 
characteristics of AuNPs: i) size, ii) surface chemistry, iii) coating materials and iv) 
shape (Wang et al., 2011 & Ahmad et al., 2017).   
 
The effect of AuNP size on toxicity has been thoroughly investigated. Tomić et al. 
(2014) showed that smaller AuNPs (10nm) induced low levels of apoptosis (20%) in 
dendritic cells (DCs), whereas larger AuNPs (50nm) demonstrated no cytotoxic effects 
on DCs. This observation is in line with the previous studies that demonstrated size 
dependent cytotoxicity of AuNPs using different cell types (Pan et al., 2007 & Yen et 
http://etd.uwc.ac.za/
33 
 
al., 2009). Another study showed that smaller AuNP sizes accumulated more readily 
in cell nuclei and organelles, thus causing DNA damage that lead to adverse effects in 
the cells (Paino et al., 2012). The absence of AuNPs inside the nucleus or organelles 
has also been reported, despite effective cellular uptake and internalization into DCs. 
This could be indicative of AuNPs entering cells then exiting the cells once it’s 
performed its function without accumulating in organelles, thus correlating with very 
low toxicity of AuNPs (Fernández et al., 2015; Fytianos et al., 2015; le Guével et al., 
2015). This points out the advantage of AuNPs compared to many other NPs, for 
example silver NPs, which cause more DNA damage when compared to AuNPs at 
similar concentrations (Singh et al., 2010). These results suggest a stringent size 
dependency of cytotoxicity, although it remains rather obscure why a particular size 
is more toxic than another (Fratoddi et al., 2015).  
 
Another key feature that functions in controlling cytotoxicity of AuNPs is surface 
chemistry. AuNPs have a positive effective surface charge (cationic) upon preparation 
but this changes when the AuNPs are in biological buffers and fluids (Lynch et al., 
2008). When AuNPs are in blood for example, plasma proteins adsorb on the surface 
spontaneously, and the surface chemistry of the AuNPs is thus not the same as the 
originally synthesised preparation (Lynch et al., 2008). Instead, the AuNPs adopt the 
physicochemical properties of the adsorbed proteins. The adsorbed protein layer can 
influence cellular uptake and particle bio-distribution, ultimately affecting particle 
cytotoxicity. Surface functionalization with various agents should therefore be 
carefully studied as it changes the particle charge and function (Fratoddi et al., 2015). 
Positively charged-polymer-coated-AuNPs showed a significant decrease in apoptosis 
when used to treat DCs, further demonstrating that surface functionalization of 
AuNPs could be safely applied in a clinical setting. In addition, the synthesis of AuNPs 
often requires toxic chemical reagents as reducing and stabilizing agents such as 
citrate and Cetyl trimethylammonium bromide (CTAB). Following synthesis the free 
chemical reagents need to be properly removed from the AuNP suspension as these 
reagents have been shown to be extremely toxic even at low concentrations (Alkilany 
and Murphy, 2010).  
 
http://etd.uwc.ac.za/
34 
 
The geometric shapes of metallic NPs can significantly influence their optical 
properties, which can be exploited for applications in diagnostics such as cellular 
tracking for example. AuNP of different shapes can be synthesised by changing the 
synthesis conditions. Figure 1.10 shows some of the possible AuNP shapes (Li et al., 
2014 & Nie et al., 2014). Altering the shape of AuNPs can influence their cytotoxicity 
and optical properties (Zhang et al., 2014). For instance, gold nanoparticle spheres 
(AuNSs) showed greater toxicity compared with gold nanostars (AuNSTs) on human 
skin fibroblasts and rat fat pad endothelial cells (Favi et al., 2015). The AuNSs were 
lethal at 40µg/mL for both cell lines, whereas the AuNSTs were less toxic at higher 
concentrations (400µg/mL), indicating that the AuNSs have a greater toxicity to ECs. 
Although AuNSs are reported to be more toxic than AuNSTs, gold nanorods (AuNRs) 
have been reported to demonstrate more toxicity than their spherical counterparts 
(Yah, 2013) due to the use of toxic chemical reagents such as CTAB for their 
preparation (Fratoddi et al., 2015). Alkilany et al. (2009) showed that cells treated 
with CTAB – coated AuNRs had a viability of 30%. When substituting CTAB with poly 
(acrylic acid) [PAA] or poly (allyamine hydrochloride) [PAH] polymers, the cell viability 
increased to more than 90% and 80% respectively (Alkilany et al., 2009). Of note, the 
three AuNRs presented approximately the same effective surface charge and size, 
indicating that the cytotoxicity is in fact caused by the surface functionalization with 
CTAB. Although deemed the more cytotoxic than its counterparts, AuNRs possess 
several advantages including large absorption cross sections, tunable longitudinal 
plasmon wavelengths, high chemical stability, and efficient photothermal conversion; 
enabling their applications as optically active agents for various biomedical 
applications, such as photothermal therapy (PTT) [Alkilany et al., 2012; Mooney et al., 
2014 & Park et al., 2014].  
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1.8.3.3. Photothermal (PTT) potential of AuNPs 
 
Photothermal therapy (PTT) is defined as the ability of NPs to effectively convert 
absorbed Near Infrared (NIR) light into heat (Pattani et al., 2015). PTT induces cell 
death via necrosis or apoptosis (Pattani et al., 2015). During necrosis, heat disrupts 
the plasma membrane, causing the cellular components to leak out with resultant 
inflammation and harm to surrounding normal tissues (Pattani et al., 2015). As 
previously stated in Section 1.7, apoptosis attenuates inflammatory activities, 
therefore skewing the PTT response towards apoptotic cell death rather than necrotic 
death which can be more favourable in clinical settings (Ali et al., 2016). 
 
Different shapes of AuNPs such as nanospheres (AuNSs) and nanorods (AuNRs) have 
been reported to have potential PTT capability, which can be attributed to their 
optical properties (Nakamura et al., 2010; Tsai et al., 2013; Mooney et al., 2014 & 
Abadeer and Murphy, 2016). These NPs can effectively convert NIR light into heat that 
will in turn eliminate cells by either necrosis or apoptosis. NP-induced PTT therefore 
holds a great promise for cancer therapy (Tsai et al., 2013; Mooney et al., 2014 & 
Abadeer and Murphy, 2016). The PTT mechanism of action using ligand-conjugated 
nanogels to selectively target cancer cells and deliver AuNPs is shown in Figure 1.11 
(Nakamura et al., 2010). Once the pegylated gold nanogel (GNG) is internalized, PTT 
can be initiated by exposing the cells to a NIR light source.  
 
 
 
 
 
 
  
Figure 1.11: Schematic illustration of the preparation of PEGylated gold nanogels (GNGs) for PTT 
application in cancer. Pegylated nanogels are made up of a nano-matrix, is functionalised with PEG 
which has affinity for ligand attachment via acetal groups. HAuCL4 is then reduced to Au (0) and AuNPs 
bind to the gel core. Upon selective targeting and cell internalization, PTT is initiated via heat causing 
cell death (Nakamura et al., 2010).  
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1.8.3.3.1. Au nanosphere-based PTT 
 
PTT using AuNSs can be achieved with pulsed or continuous wave (CW) visible light 
spectrum lasers due to the Surface Plasmon Resonance (SPR) absorption in the visible 
light region of the electromagnetic spectrum (Huang and El-Sayed, 2010). AuNSs can 
therefore be used for the treatment of shallow cancers (e.g. skin cancer). The first 
comprehensive study using pulsed laser and AuNSs was performed for the selective 
and highly localized photothermolysis of lymphocytes cells (Pitsillides et al., 2003). 
The study by Pitsillides et al. (2003) showed that lymphocytes exposed to mAb-
conjugated AuNSs and nanosecond laser pulses showed cell death whereas adjacent 
cells remained viable. Cell death is attributed mainly to cavitation damage caused by 
the generation of micro-scale bubbles around the AuNSs (Huang and El-Sayed, 2010). 
Similar in vitro studies have been performed for the treatment of cervical and breast 
cancer using the laser induced-bubbles produced by nanosecond laser pulses (Zharov 
et al., 2004, 2005). The treatment modality has since been demonstrated for in vivo 
tumour ablation in a rat cancer model (Hleb et al., 2008). Although visible light is 
successful in destroying cells labelled with spherical-shaped AuNPs, for a more 
practical application of PTT, deep tissue penetration is required. Near-infrared (NIR) 
external radiation is capable of achieving this, such that it can penetrate up to 10cm 
in soft tissues at the NIR tissue transmission window, 650−900nm (Weissleder, 2001). 
 
 
1.8.3.3.2. Au nanorod-based PTT 
 
The increase of PTT nanosystems in recent years is largely attributed to the 
emergence of the AuNRs.  Due to their non-spherical geometry, AuNRs have both 
transverse and longitudinal plasmon (Pérez-Juste et al., 2005). Their absorption 
profile includes two absorption bands: one due to light absorbed along the short axis 
(transverse) and the other due to absorption along the long axis (longitudinal). As the 
rod length increases, so does the longitudinal band red shift together with an 
increase in the extinction coefficient (Fratoddi et al., 2015). The longitudinal plasmon 
wavelength is approximately linearly dependent on the length-to-diameter ratio, 
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which is usually called the aspect ratio (Ni et al., 2008). The aspect ratio of the AuNRs 
can be varied from low to high in order to tune their peak optical absorption 
wavelength. By changing the shape and composition of the nanoparticle to rod-
shaped, the surface plasmon absorption can be shifted into the NIR transmission 
window (Chen et al., 2007 & Wiley et al., 2007). 
 
AuNR-based PTT was first reported in 2006, where mAb-conjugated AuNRs were 
applied to selectively eliminate cancer cells through efficient photothermal 
conversion (Huang et al., 2006). Since then, great efforts have been expended on this 
aspect, including both in vitro and in vivo photothermal heating and theoretical 
modelling to study the PTT performance and the design of more effective PTT agents 
(Huang et al., 2010 & Zhang et al., 2014).  For example, a computationally guided 
photothermal tumour therapeutic method that combined the quantitative bio-
distribution data of AuNRs with computational modelling enabled photothermal 
temperature gradients in three-dimensional tissues (von Maltzahn et al., 2009). In 
addition, owing to the advantage of conjugation with cancer targeting moieties, 
AuNRs have been widely used in the precise control of drug delivery in cells. A 
controlled delivery was demonstrated by encapsulating AuNRs in protein-shell 
microbubbles (AuMBs) and then modifying the AuMBs with anti-VEGFR2 to target 
angiogenesis markers (Wang et al., 2014). The AuMBs were destroyed by ultrasound 
to release the AuNRs and then PTT was activated. The ultrasound-induced MB 
disruption enhanced the cellular delivery and therapeutic effects of AuNRs (Wang et 
al., 2014).  
 
Initially, several reports concerning the mechanism of PTT were only conducted in 
vitro and focus on a single protein or pathway. To better understand the cellular 
responses to PTT, systematic in vivo studies have been conducted. One such study 
showed that rifampicin (RF)-targeting enhanced entry of AuNRs into cells and a 
decrease in exocytosis from the cells (Ali et al., 2014). Enhanced PTT effect of RF-
conjugated AuNRs in xenograft mice was due to cytochrome c and p53-related 
apoptosis mechanisms (Ali et al., 2017). There was no long-term (15-month) toxicity 
of the AuNRs in vivo. Together, these data demonstrate that the AuNRs-PTT platform 
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is effective and safe for cancer therapy in mouse models. These studies provide a 
strong framework for the translation of PTT to clinical studies. 
 
 
1.9. Aim(s) and objectives of the study 
 
1.9.1. Aim(s) 
 
The aim of the study was to develop a nanoparticle-based targeted drug delivery 
system using peptide-directed AuNRs as a delivery vehicle and to evaluate whether 
photothermal therapy could enhance the therapeutic effect of the AuNRs on cancer 
cells.  
 
 
1.9.2. Objectives 
 
 To synthesise, functionalise and characterise AuNRs via the seed-mediated 
method. 
 To identify PHB-expressing cells via immunocytochemistry.  
 To evaluate the cytotoxic effects of the PHB-targeted-nanotherapy on PHB 
expressing cancer cells 
 To investigate whether laser treatment would enhance the PTT effect of the PHB-
targeted AuNRs. 
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Chapter Two: Materials and methods 
  
2.1. Reagents, Equipment and Suppliers 
 
 
Supplier Reagent 
Anaspec Adipose Homing Peptide 
Sequence: D(CKGGRAKDC) 
 
Gibco Foetal bovine serum (FBS) 
Penicillin/streptomycin 
Trypan blue stain (0.4%) 
Trypsin (2.5%) 
 
GL Biochem D(KLAKKLAK)2 peptide 
Sequence: D(KLAKLAK)2-DEVD-SH 
 
BioLegend® Purified rabbit anti-prohibitin antibody 
 
Kimix Nitric acid (HNO3) 
Life Technologies Alexa-Fluor-488 secondary antibody 
Lonza Dulbecco’s Modified Eagle’s Medium (DMEM) 
DMEM: F12 Media 
Phosphate buffered saline (PBS) 
 
Merck Hydrochloric acid (HCl) 
 
Prochimia Surfaces PEG-OH, 2-{2-[2-(2-{2-[2-(1-mercaptoundec-
11-yloxy) ethoxy]-ethoxy}-ethoxy)-ethoxy]-
ethoxy}-ethanol [C23H48O7S] 
 
PEG-biotin, N-(2-{2-[2-(2-{2-[2-(1-
mercaptoundec-11-yloxy)-ethoxy]-ethoxy}-
ethoxy)-ethoxy]-ethoxy}-ethyl) biotinamide 
[C33H63N3O8S2] 
 
Roche Bovine serum albumin (BSA)  
Insulin 
Water-soluble Tetrazolium, 2-(4-Iodophenyl)-
3-(4-nitrophenyl)-5-(2,4disulfophenyl)-2H-
tetrazolium [WST-1] 
 
Sigma-Aldrich L-Ascorbic acid 
Table 2.1 Reagents and suppliers 
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Streptavidin  
Cetyl trimethylammonium bromide  
Sodium borohydride  
Gold (III)chloride trihydrate 
Dimethyl sulphoxide (DMSO) 
Hydrocortisone 
FlouroshieldTM with Dapi  
Paraformaldehyde 
Human Epidermal growth factor (EGF)  
Silver nitrate (AgNO3) 
 
 
 Supplier               Instrument  
American Instrument 
Exchange, Inc. 
 
Sorvall TC6 centrifuge H 400 
Carl Zeiss TEC NAI F20 TEM microscope 
LSM 780 Confocal microscope 
 
Lasec  BASIC 20 pH-Meter  
BMG LABTECH POLAR star Omega Microplate reader 
BD Biosciences BD CSampler™ Flow Cytometer 
Eppendorf Eppendorf 5417 R microcentrifuge with 
rotor F45-3011 
 
Invitrogen Countess™ Automated cell counter 
 
Labnet international Inc. Vortex Mixer 
 
Leica Leica Bond Autostainer 
 
Malvern Zeta Sizer Nano Series 
 
Nikon TMS-F Inverted light Microscope 
 
Qianbaihe  Trading (Wuhan) 
Co., Ltd. 
780nm (100mW) Infrared Laser Diode 
Module Dot 
 
Thermo Fisher Scientific Water Jacked CO2 incubator 
 
Varian Varian 710-ES ICP Optical Emission 
Spectrometer 
Table 2.2: Equipment used 
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2.2. Research methodology 
 
2.2.1. Synthesis of AuNRs 
 
AuNRs were prepared by the seed-mediated growth method in aqueous solutions 
through changing the seed-to-Au (III) ions ratio in the growth solution, following a 
method adapted from Jia et al. (2015). Cetyltrimethylammonium bromide (CTAB) was 
employed as the stabilizing surfactant. CTAB was dissolved by heating to 50°C while 
stirring and then cooling the solution to 25°C prior to use.  
 
 
2.2.1.1. Preparation of the seeding solution  
 
The seed solution was made by adding 0.6ml of ice cold freshly prepared Sodium 
borohydride (NaBH4) (0.01M) (Sigma – Aldrich) to a solution composed of 0.25ml 
Gold (III) chloride trihydrate (HAuCl4) (0.01M) (Sigma – Aldrich) and 9.75ml of CTAB 
(0.1M) (Sigma – Aldrich). The resultant solution was stirred vigorously for 2min then 
left undisturbed at room temperature for 2-4hrs, until solution changed colour from 
yellow to pinkish/brown (Figure 2.1).  
 
 
 
 
 
 
 
 
Figure 2.1: Schematic for preparation of AuNR seeds. 
Note: The seeding solution was always freshly prepared before every AuNR synthesis.  
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2.2.1.2. Preparation of the growth solution 
 
The growth solution was prepared by the sequential addition of 0.5ml HAuCl4 
(0.01M), 0.1ml Silver nitrate (AgNO3) (0.01M) (Sigma – Aldrich) and 0.2ml 
Hydrochloric acid (HCl) (1M) (Merck) to CTAB (0.1M) as depicted in Table 2.3. The 
volume of CTAB varied depending on the seed-to-Au (III) ions ratio in the growth 
solution.  The ratios are named GmSn, where G denotes the growth solution, S refers 
to the seed solution, m is the volume of the surfactant solution i.e. CTAB used in 
preparing the growth solution with the volumes of the other ingredient solutions 
kept unchanged, and n is the volume of the seed solution (Jia et al., 2015). The units 
of m and n are both ml. Three ratios were used in this study i.e. G6S4, G8S2 and 
G9S1.  A freshly prepared 0.08ml ascorbic acid solution (0.1M) (Sigma – Aldrich) was 
added while stirring the solution rapidly. Once the solution became colourless, seed 
solution was added while the mixture was vigorously stirred. The resultant solution 
was stirred for 2min and left undisturbed at 25°C overnight. The appearance of a 
wine red colour after 24hrs indicated the formation of AuNPs as shown in Figure 2.2. 
 
 
 
 
Solutions use for 
the preparation of 
the growth solution  
AuNR preparations 
G6S4 G8S2 G9S1 
HAuCl4 (0.01M), 0.5 0.5 0.5 
AgNO3 (0.01M) 0.1 0.1 0.1 
HCl (1M) 0.2 0.2 0.2 
Ascorbic acid (0.1M) 0.08 0.08 0.08 
CTAB (0.1M) 6 8 9 
Au Seed  4 2 1 
 
 
 
Table 2.3: The volumes (ml) of solutions used for the preparation of the AuNR 
growth solution 
 
Note: G = growth solution, S = the seed solution, m = volume of CTAB (ml) and n = volume of the 
seed solution (ml) 
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The final reaction mixture for AuNR synthesis contains the desired AuNRs as well as a 
variety of AuNPs of different shapes (spherical, cubic, etc.) as shown in Figure 2.3. To 
obtain a homogeneous population of AuNRs, two cycles of centrifugation were 
carried out. After the synthesis, all reaction products (spheres, cubes, and rods) were 
first isolated and purified from the excess CTAB through centrifugation at high rpm 
(10600 rpm) using a bench top centrifuge (Eppendorf 5417 R microcentrifuge with 
rotor F45-30-11). Then, AuNR separation was afforded through a second cycle of 
centrifugation (6000 rpm)(Eppendorf 5417 R microcentrifuge with rotor F45-30-11) 
adapted from the method reported by Scaletti et al. (2014).  
 
 
 
 
 
 
 
2.2.2. Functionalization of AuNRs 
 
The CTAB stabilized AuNRs were bi-functionalised by conjugating the targeting (AHP) 
peptide, sequence: D(CKGGRAKDC) (Anaspec) and therapeutic D(KLAKLAK)2 peptide, 
sequence: D(KLAKLAK)2-DEVD-SH (GL Biochem)  to the NP through ligand exchange. 
Supernatant 
 
Figure 2.2: Schematic for the preparation of CTAB-capped AuNRs. 
Figure 2.3: Separation of AuNR from other shapes by differential centrifugation. 
 
Pellet 
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An aqueous solution containing AuNRs, PEG–OH (2-{2-[2-(2-{2-[2-(1-mercaptoundec-
11-yloxy) ethoxy]-ethoxy}-ethoxy)-ethoxy]-ethoxy}-ethanol [C23H48O7S] (Prochimia 
Surfaces), PEG–biotin (N-(2-{2-[2-(2-{2-[2-(1-mercaptoundec-11-yloxy)-ethoxy]-
ethoxy}-ethoxy) ethoxy]-ethoxy}-ethyl) biotinamide [C33H63N3O8S2](Prochimia 
Surfaces) and the KLAK peptides were stirred at 4°C for 24hrs. The ingredients were 
combined in the molar ratio of 9 ([PEG]–OH): 1 (PEG–biotin): 1 (peptide) according to 
Sibuyi et al. (2017) with slight modifications. A free thiol group in the cysteine residue 
at the C-terminal of the peptides (KLAK peptide and PEG–OH) facilitated its covalent 
attachment to the AuNR surface. The functionalised AuNRs were washed twice with 
dH2O. The AHP peptide was conjugated to the AuNRs through biotin–streptavidin 
linkage. The biotinylated peptides and streptavidin (Sigma- Aldrich) were added to 
the AuNRs in a 1:1 molar ratio and stirred at 25°C for 1hr. The AuNRs were washed 
and re-suspended in dH2O. The resulting AuNRs and acronyms used are shown in 
Table 2.4 and the expected AuNR designs are schematically shown in Figure 2.4.  
 
 
 
  
AuNR 
conjugates 
   
Acronym 
  
Attached molecules 
PEG-
OH 
 PEG- 
Biotin 
Biotin–
AHP 
 KLA-
DEVD-SH 
AuNR-
CTAB 
G - - - - 
AuNR-PEG GP + + - - 
AuNR-AHP AG + + + - 
AuNR-
KLAK 
GK + + - + 
AuNR-
AHP-KLAK 
AGK + + + + 
 
 
 
Table 2.4: Description and characteristics of various gold nanorods. 
 
Note: AHP = D(CKGGRAKDC) targeting peptide; KLAK =  D(KLAKLAK)2-DEVD-SH therapeutic peptide; 
peptide, - = absence; + = presence. AuNR-CTAB = CTAB-coated AuNRs; AuNR-PEG = PEG-coated 
AuNRs; AuNR–AHP = AuNP with a targeting peptide; AuNP–KLAK = Nontargeted AuNP with 
therapeutic peptide; AuNP–AHP–KLAK = AuNP with AHP and therapeutic peptide (PHB-targeted 
nanotherapy). 
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2.2.3. Characterisation of AuNRs 
 
2.2.3.1. Optical properties: UV-Vis spectroscopy 
 
The resulting AuNRs were characterized after modification by UV-Vis absorption 
spectroscopy using a POLAR star Omega Microplate reader (BMG LABTECH) to study 
the peak absorption band (SPR) in a wavelength range of 350-1000nm.  
 
 
2.2.3.2. Stability of AuNRs 
 
The in vitro stability of the AuNRs in different buffer solutions was measured 
according to a protocol reported by Elbagory et al. (2016), with slight modifications. 
The AuNRs were incubated with six different buffer solutions i.e. 0.5% Bovine Serum 
Albumin (BSA) (Roche); 1X Phosphate buffered saline (PBS) [Lonza]; Dulbecco’s 
Modified Eagle’s Medium (DMEM) [Lonza]; 10% Foetal bovine serum (FBS) [Gibco]; 
Figure 2.4: Schematic of the expected AuNP design. AGK = AuNRs has both targeting and therapeutic 
peptides, G = CTAB coated AuNRs, GP = pegylated AuNRs, GK = AuNRs with therapeutic peptide, and 
AG = targeted pegylated AuNRs.   
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DMEM [complete, containing 10% (FBS) and 0.1% Pen/Strep (Gibco)] and dH2O. The 
pegylated AuNRs were centrifuged at 10000rpm using a bench top centrifuge 
(Eppendorf 5417 R microcentrifuge with rotor F45-30-11) for 15min. The pellets were 
washed three times with autoclaved dH2O. The AuNRs were then re-suspended in 
1ml dH2O. The AuNRs and the buffer solutions were mixed in a 6:4 ratio in a 96-well 
plate and the stability of the AuNPs was evaluated by measuring the changes in UV-
Vis spectra after 3, 6, 12 and 24hrs. The SPR of the AuNRs were measured using the 
POLAR star Omega Microplate reader.   
 
 
2.2.3.3. Electrochemical charge of AuNRs 
 
Zeta potential measurements of the AuNR conjugates were performed immediately 
after synthesis using a Malvern Zetasizer Nano ZS operating with a variable power (5–
50mW) He-Ne laser at 633nm.  
 
 
2.2.3.4. Size and morphology: High Resolution-Transmission Electron 
Microscopy (HR-TEM) and Energy Dispersive X-ray Spectroscopy 
(EDX) Analysis 
 
To study the morphology of the AuNRs, HR-TEM micrographs were obtained on a 
field emission TEC NAI F20 TEM microscope (Carl Zeiss) [Physics Department, UWC]. 
Samples were prepared by drop-coating each test sample solution onto a copper (Cu) 
grid, supported by a thin film of amorphous carbon. This was then dried under a 
Xenon lamp for 10min and the samples were analysed under the microscope. 
Transmission electron micrographs were obtained in a bright field mode at an 
accelerating voltage of 200kV.  
 
Energy Dispersive X-ray Spectroscopy (EDX) measures the elemental and chemical 
analysis of the nanomaterial being probed (Rao and Biswas, 2009). EDX was 
measured from the same samples used for HR-TEM. Energy dispersive X-ray spectra 
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were measured using an EDAX liquid nitrogen cooled Lithium doped Silicon detector 
connected to the TEM. 
 
 
2.2.4. Cell culture 
 
The cell lines (Table 2.5) used in this study were obtained from the American Type 
Culture Collection (ATCC). Vials containing the frozen cells were removed from the -
120˚C freezer and allowed to thaw at 25˚C. The cells were transferred into a 15ml 
tube containing complete media (pre-warmed to 25˚C) with respective supplements 
(Table 2.5) and centrifuged at 3000rpm in a bench top Sorvall TC6 centrifuge H400 for 
5min.  The supernatant was discarded and the cell pellet was re-suspended in their 
respective supplemented media. The cells were cultured in 25cm2 cell culture flasks 
(SPL Life Sciences) which were incubated in a water-jacketed CO2 incubator (Thermo 
Fisher Scientific) at 37˚C and 5% CO2.  The cell culture medium was changed every 
third day until the cells reached 70-90% confluency. The procedures were performed 
in the Biological Safety Cabinet (Laminar flow) using aseptic techniques. 
 
 
 
 
Tissue 
origin  
Acronym Disease Growth 
media  
Supplements 
Colon  Caco-2 Colorectal 
Adenocarcinoma 
DMEM  1% pen/strep 
10% FBS 
     
Lung  A549 carcinoma DMEM- 
F12  
1% pen/strep 
10% FBS 
     
Ovary  Caov-3 Adenocarcinoma DMEM  1% pen/strep 
10% FBS 
     
Ovary  SKOV-3 Adenocarcinoma RPMI  1% pen/strep 
10% FBS 
     
Cervix Ca Ski Epidermoid 
Carcinoma 
RPMI  1% pen/strep 
10% FBS 
     
Table 2.5: Human cell cultures used in this study. 
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Liver  Hep G2 Hepatocellular 
carcinoma 
DMEM  
 
1% pen/strep 
10 % FBS 
     
Prostate  LNCaP Carcinoma RPMI  
 
1% pen/strep 
10 % FBS 
     
Breast  MCF7 Adenocarcinoma DMEM  
 
1% pen/strep 
10 % FBS 
     
Prostate  PC-3 
 
Grade IV 
adenocarcinoma 
RPMI  
 
1% pen/strep 
10% FBS 
     
Breast 
 
MCF-12A 
 
Epithelial 
spontaneous 
immortalization 
 
DMEM-
F12  
 
1% pen/strep, 
10% FBS, 
10֯µg/ml 
Insulin, 
500ng/ml 
Hydrocortisone 
and 20ng/ml 
EGF 
     
Kidney  HEK-293 Spontaneous 
transformation 
with adenovirus 
5 DNA 
DMEM  
 
 
 
1% pen/strep 
10% FBS 
     
Brain  U87 Glioblastoma  DMEM  
 
1% pen/strep 
10% FBS 
     
Lung  H157 Squamous cell 
carcinoma 
RPMI  
 
1% pen/strep 
10% FBS 
 
 
 
2.2.4.1. Sub-culturing of cells 
 
Once the cells had reached 70-80% confluency, the medium in the flask was 
decanted. Thereafter, the cells were washed with PBS. The PBS was then discarded 
and the cells were trypsinized by adding 3ml 2X trypsin (Gibco) to the flask, which 
was then incubated at 37˚C for 1-3min. The detachment of the cells from the flask 
was periodically inspected using a Nikon TMS-F light microscope. As soon as the cells 
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start to round up, the detachment was facilitated by gently tapping of the flask on a 
hard surface to dislodge the cells. Twice the volume (6ml) of medium was added to 
the flask to inactivate the trypsin. The cells were then transferred to pre-labelled 
15ml conical tubes and centrifuged at 3000rpm in a bench top Sorvall TC6 centrifuge 
H400 for 5min. The supernatant was discarded and the cells were re-suspended in 1-
5ml complete media.  
 
 
2.2.4.2. Cell count: Trypan Blue Exclusion Assay 
 
Cell count was determined using the trypan blue exclusion assay following the 
manufacturer’s instructions. Briefly, a 10µl aliquot of the cell suspension was mixed 
with an equal volume of 0.4% trypan blue dye (Gibco). The mixture was loaded into a 
Countess™ chamber slide (Life technologies). The number of viable cells was assessed 
using the Countess® Automated Cell Counter (Invitrogen), as described by the 
manufacturer.  
 
 
2.2.4.3. Storage of cells 
 
The cells were trypsinized as described in Section 2.2.4.1. The cells were recovered by 
centrifugation and re-suspended in complete medium containing 10% Dimethyl 
sulphoxide (DMSO) (Sigma-Aldrich). The cell suspension was aliquoted into 2ml cryo-
vials and stored at -120˚C until further use. 
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2.2.5. Localization of PHB expression using immunocytochemistry (ICC) 
 
2.2.5.1. Chromogenic staining 
 
2.2.5.1.1. Cell fixation  
 
The cells were cultured on glass slides (76mm x 26mm; 1.0mm to 1.2mm thick) at 
37°C until 80% confluency was reached. The cells were washed three times (3min for 
each wash) with 1X PBS. The cells were then fixed in 4% paraformaldehyde (PFA) 
(Sigma – Aldrich) at 25°C for 20min. Following fixation, the cells were washed three 
times (3min for each wash) with 1X PBS. 
 
 
2.2.5.1.2. Immunocytochemical Staining 
 
Immunocytochemical (ICC) staining was performed at The National Health Laboratory 
Services at Tygerberg Hospital. The cancer cells (Caco-2, PC-3, U-87, A549, Ca0v-3, 
Caski, H157, Hek-293, Hep-G2, LnCap, MCF-7 and SKOV-3) were stained with purified 
rabbit anti-prohibitin antibody (1:100 dilution) (Biolegend). All staining, washing and 
antibody incubations were performed in a Leica Bond Autostainer (Leica), following 
the steps shown in Table 2.6.  
 
 
 
 
Step Type Incubation 
Time (min) 
Temperature Dispense 
Type 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
Peroxide Block 
Bond Wash Soln 
Bond Wash Soln 
Bond Wash Soln 
Primary Antibody 
Bond Wash Soln 
Bond Wash Soln 
Bond Wash Soln 
Post Primary 
Bond Wash Soln 
Bond Wash Soln 
5  
0 
0 
15 
0 
0 
0 
8 
2 
2 
2 
Ambient 
Ambient 
Ambient 
Ambient 
Ambient 
Ambient 
Ambient 
Ambient 
Ambient 
Ambient 
Ambient 
Selected vol. 
Selected vol. 
Open 
Selected vol. 
Selected vol. 
Selected vol. 
Selected vol. 
Selected vol. 
Selected vol. 
Selected vol. 
Selected vol. 
Table 2.6: The ICC staining protocol. 
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12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
 
Bond Wash Soln 
Polymer 
Bond Wash Soln 
Bond Wash Soln 
Deionized water 
Deionized water 
Mixed DAB refine 
Deionized water 
Deionized water 
Deionized water 
Hematoxylin 
Deionized water 
 
8 
2 
2 
0 
10 
0 
0 
0 
5 
0 
0 
0 
 
Ambient 
Ambient 
Ambient 
Ambient 
Ambient 
Ambient 
Ambient 
Ambient 
Ambient 
Ambient 
Ambient 
Ambient 
 
Selected vol. 
Selected vol. 
Selected vol. 
Selected vol. 
Selected vol. 
Selected vol. 
Selected vol. 
Selected vol. 
Selected vol. 
Selected vol. 
Selected vol. 
Selected vol. 
 
 
 
 
 
2.2.5.1.3. Rehydration 
 
After the staining procedure, the samples were rehydrated and cleared manually 
using the steps outlined in Table 2.7. Images were then taken at the Department 
Medical Biosciences (UWC) with an inverted light microscope (Nikon TMS-F) at 40X 
magnification. 
 
 
 
Step Solution Duration  
1 
2 
3 
4 
5 
6 
7 
 
70% Alcohol 
70% Alcohol 
70% Alcohol 
70% Alcohol 
70% Alcohol 
Xylene 
Xylene 
5 Dips 
5 Dips 
5 Dips 
5 Dips 
5 Dips 
Dip for 1min 
Dip for 1min 
 
 
 
 
 
 
Table 2.7: The rehydration protocol 
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2.2.5.2. Immunofluorescence 
 
2.2.5.2.1. Fixing of cells 
 
The cancer cells (Caco-2, PC-3 and U-87) were cultured onto sterilised coverslips in 6-
well plates at a cell density of 2 x 105 cells/ml. The plates were placed in a water-
jacketed CO2 incubator at 37˚C and the cells were cultured until they reached 50–60% 
confluency. The media was removed from the cells and washed twice with 1X PBS. 
The PBS was then discarded and the cells were fixed with 4% PFA for 10min at 25˚C. 
The cells were washed twice with 1X PBS.  
 
 
2.2.5.2.2. Antibody binding and microscopy 
 
The coverslips containing the fixed cells were incubated at 4˚C for 1hr in blocking 
buffer (1X PBS, containing 0.5% BSA). The cells were washed thrice with 1X PBS. The 
cells were incubated in purified rabbit anti-prohibitin antibody (diluted 1:100 in 
blocking buffer) at 4°C overnight. The cells were washed thrice in 1X PBS for 5min and 
then incubated in anti-rabbit Alexa Fluor-488 secondary antibody (diluted 1:1000 in 
blocking buffer) (Life technologies) at 4°C for 2hrs. The cells were washed thrice with 
1X PBS. The coverslips were transferred onto the microscope slides containing 
Fluoroshield DAPI mounting media (Sigma – Aldrich). The images were captured at 
60X magnification under oil immersion using the fluorescent Carl Zeiss LSM 780 
Confocal microscope with Elyra S.1 super resolution platform (Carl Zeiss) at the 
Central Analytical Facility Imaging Unit at Stellenbosch University.   
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2.2.6. Therapeutic potential of the targeted nanotherapy 
 
2.2.6.1. Effect of the AuNRs on cell proliferation: WST-1 Assay 
 
The cytotoxicity of the AuNRs was evaluated using water-soluble tetrazolium salts 
(WST) -1 cell proliferation reagent as described by the manufacturer (Roche). The 
cells (Caco-2, PC-3, U-87 and MCF-12A) were seeded at a density of 1x105 cells/well in 
a 96 well plate (100µl/well).  The cells were incubated at in a water-jacketed CO2 
incubator at 37˚C and 5% CO2. After 24hrs, the media was removed from each well 
and replaced with 100µl fresh media containing increasing concentrations of the 
AuNR conjugates ranging from 3µg/ml to 1000µg/ml. All treatments were done for 
24hrs in triplicate. The untreated cells served as negative controls, while cells treated 
with 6% DMSO served as a positive control as DMSO above 4% has a toxic effect on 
mammalian cells according to literature (Vergara et al., 2014 & Siddiqui et al., 2016). 
After 24hrs, 10µl WST-1 cell proliferation reagent was added to all the wells. 
Additional wells containing the same range of AuNR concentrations was used to 
determine if there was interference of the AuNR with the assay. The plate was 
covered in foil and the cells were incubated at 37°C for 3hrs and then placed on a 
shaker for 1min.    
 
The absorbance of the formazan product formed was measured at 440nm using a 
PolarSTAR Omega plate reader. Absorbance readings at 630nm  were measured and 
used to eliminate background. The percentage of cell viability was calculated as 
shown using the formula below.  
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2.2.6.2. Quantification of cellular uptake of AuNR  
 
The amount of AuNRs taken up by cells was quantified by Inductively Coupled Plasma 
Optical Emission Spectroscopy (ICP-OES). Caco-2 cells were seeded in 12 well cell 
culture plates (Sigma). After reaching 80% confluence, the cells were treated with 
500µl of 200µg/ml of pegylated NRs (GP) and NRs functionalised with targeting and 
therapeutic peptides (AGK). The untreated cells and cells treated with 6% DMSO 
were included as negative and positive controls, respectively.  After 24hrs, the cells 
were detached using 2X trypsin and transferred into the corresponding 15ml tubes. 
The cells were centrifuged at 3000rpm in a bench top Sorvall TC6 centrifuge for 3min, 
the pellet was washed once with 2ml 1X PBS. The samples were digested by 
incubation at 90°C for 2hrs in 2ml Aqua Regia solution (3:1 HCl: HNO3 (Kimix)). 
Thereafter the samples were diluted to 10ml with 2% HCl. In order to calculate the 
percentage of AuNRs taken up by cells, the concentration of Au present in a 500µl of 
200µg/ml preparation of AGK and PG needed to be established. This was done by 
centrifuging a 500µl aliquot (at a concentration of 200µg/ml) of the AGK and PG 
AuNPs at 10 000rpm using a bench top centrifuge (Eppendorf 5417 R microcentrifuge 
with rotor F45-30-11). The pellet was also digested by incubation at 90°C for 2hrs in 
2ml aqua regia solution, which was then diluted to 10ml with 2% HCl. At this stage, 
the cell suspension could be stored at −20°C until analysis. These samples were 
analysed for total gold content by a Varian 710-ES ICP Optical Emission Spectrometer 
(Varian) at the Chemistry Department (University of the Western Cape). The 
measurement was repeated 3 times for each sample submitted, the values reported 
were based on a calibration curve using a gold ICP standard (Sigma - Aldrich). The 
formula below was used to calculate the percentage of gold internalized by the cells: 
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2.2.6.3. Analysis of apoptotic cell death using the APOPercentageTM 
Assay 
 
The APOPercentageTM apoptosis assay (Biocolor, UK) was used to quantify the 
percentage apoptotic cells using the protocol described by Meyer et al. (2008). The 
cells were seeded in 12 well cell culture plates at a density of 2x105 cells/ml. The cells 
were incubated for 24hrs at 37oC. The culture media was then removed and replaced 
with media containing 200µg/ml of the AuNRs. The cells were incubated for 24hrs at 
37°C. Untreated and cells treated with 6% DMSO served as negative and positive 
controls, respectively. The cells were detached using 2X trypsin and transferred to 
their corresponding tubes. Cells were harvested by centrifugation at 3000rpm in a 
bench top Sorvall TC6 centrifuge H400 for 5min at 25oC. The supernatant was 
discarded and the pellet was gently re-suspended in 250μl APOPercentageTM dye 
(diluted 1:160 in growth medium). The cells were incubated for further 30min at 
37oC.  PBS (2ml of 1X concentration) was then added to each tube, which was 
centrifuged at 3000rpm in a bench top Sorvall TC6 centrifuge H400 for 5min at 25oC. 
The supernatant was discarded and the cell pellets were re-suspended in 300μl of 1X 
PBS. Cell staining was measured using the BD Accuri flow cytometer (BD Biosciences). 
Acquisition was done in log mode and a maximum of 10000 to 30000 events per 
sample were acquired and analysed using the BD CSampler software. 
 
 
2.2.6.4. Photothermal therapy 
 
Caco-2 cells were seeded in 96-well cell culture plates at a density of 1x105 cells/ml 
and incubated for 24hrs at 37°C. The culture media was then removed and replaced 
with media containing 500µg/ml of the AuNRs containing the targeting peptide (AG). 
The cells were then incubated for 30min at 37°C to allow for uptake of the AuNR. The 
negative (untreated) and positive (6% DMSO) controls were included. Following 
incubation, the cells were washed with 1X PBS and HAMS-F12 media was added to 
the cells to avoid interference of phenol red in DMEM. Two areas of the wells were 
exposed to a 780nm (100mW) Infrared Laser Diode Module Dot with Adapter, 
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6x68mm Focusable (Qianbaihe Trading (Wuhan) Co., Ltd.), with an exposure time of 
30sec to 15min. Following exposure, the media was replaced with DMEM and 
incubated at 37°C for further 24hrs. Following incubation, cell viability was assessed 
by the WST-1 assay as described in Section 2.2.6.1.  
 
 
2.2.6.5. Statistical analysis  
 
Statistical and multiple-comparison analyses were performed within each group of 
cell viability assays performed in this study. Data were expressed as the mean ± 
standard deviation of the three replicates. Statistical analysis was conducted using 
the GraphPad Prism 6 and two-tailed Student’s t-test. Differences among three or 
more groups were analyzed by two-way analysis of variance. Differences with p < 
0.05 were considered to be statistically significant. 
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Chapter Three: Synthesis and characterization of peptide functionalised 
gold nanorods 
 
3.1. Introduction 
 
AuNPs have been applied in several industrial and biomedical procedures in the 
recent past. The versatility of AuNPs depends on their physicochemical properties 
that can be fine-tuned in order to facilitate their applications in diagnostics and 
therapeutics (Elder et al., 2007 & Dykman and Khlebtsov, 2011). The usefulness of 
AuNPs depends on their physical, chemical, electronic and optical properties, which 
hinges on the synthetic design which require considerable control of their 
composition, size, shape, stability and dispersion properties (Sosibo et al., 2015).  
 
Although some studies suggest that gold is biologically inert (Brown et al., 2008), the 
physicochemical properties of AuNPs have been associated with undesirable adverse 
effects on biological systems (Smolkova et al., 2015). Several independent in vitro and 
in vivo studies have demonstrated the toxicity of AuNPs (Söderstjerna et al., 2014 & 
Wan et al., 2015). However this toxicity can be exploited if channelled to specific cells 
by modifying the AuNP surface with biomolecules to facilitate their target specific 
uptake through targeted delivery (Kumar et al., 2012). The use of AuNPs as drug 
delivery vehicles has shown great potential in pre-clinical studies, which have 
demonstrated that AuNP/biomolecule or AuNP/drug conjugates are more efficient 
than the biomolecules or drugs on their own (Tomuleasa et al., 2012 & Li et al., 
2016).  
 
In the current study a PHB-targeted nanotherapy was developed by conjugating a 
pro-apoptotic D(KLAKLAK)2) and a PHB-targeting (AHP) peptide to AuNRs. A recent 
study by Sibuyi et al. (2017) showed that gold nanospheres (AuNSs) functionalised 
with these two peptides successfully induced apoptosis in Caco-2 cells, which express 
AHP, the target for PHB. The same strategy was used in this study. However, the 
shape of the AuNP was changed from AuNSs to gold nanorods (AuNR) in order to 
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exploit the photothermal (PTT) potential of nanorods for the elimination of cancer 
cells. The unique plasmonic properties of AuNRs can be exploited in PTT by 
coherently photo-exciting their conduction electrons to induce surface plasmon 
oscillations. Upon surface plasmon formation, nonradiative relaxation occurs where 
the electrons return to a less active state, and the energy is released as a phonon that 
then generates localized heat that can be transferred to the surrounding 
environment (Hartland, 2011). AuNRs exhibit better NIR absorption cross-section 
than any other AuNPs (Hu et al., 2006) and demonstrate extremely efficient NIR 
induced PTT heat conversion (von Maltzahn et al., 2009). AuNRs with a length of 
40nm, a diameter of 10nm and a longitudinal plasmon resonance of approximately 
800nm is most commonly used for PTT (Ni et al., 2008; Chen et al., 2010).   
 
This chapter reports on the synthesis of AuNRs that were functionalised with two 
peptides [a targeting peptide, AHP, and a pro-apoptotic peptide, D(KLAKLAK)2. The 
design (Figure 3.1) of the AuNRs was based on two previous studies (Sosibo et al., 
2015 & Sibuyi et al., 2017). AuNR were synthesised using the seed-mediated growth 
method. Naked AuNRs tend to be unstable in organic solvents, therefore, to prevent 
aggregation in solution PEG molecules were used as a stabilizer and emulsifying 
agent. Encapsulation of the metal core with PEG creates a dielectric shell around the 
metal core, this provides means of protection for the AuNRs from the surrounding 
environment or opsonisation when used in biological systems. The AuNRs were 
stabilised by pegylation using a mixture of SH-PEG-OH and SH-PEG-Biotin as 
described by Sosibo et al. (2015). The thiol (SH) group on SH-PEG-OH and SH-PEG-
Biotin facilitated the conjugation of PEG to the AuNR surface. The D(KLAKLAK)2 
peptide was similarly thiolated to facilitate conjugation to the AuNR surface as 
described by Sibuyi et al. (2017), while AHP contained a streptavidin tag to facilitate 
binding of the peptide to PEG-Biotin. Using this design strategy, four different types 
of AuNRs samples (GP, AGK, GK and AG) were synthesised as shown in Figure 3.1.  
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3.2. Results and Discussion 
 
3.2.1. Synthesis of AuNRs 
 
AuNR samples were prepared by the seed-mediated growth method using CTAB as 
the stabilizing surfactant as described in Chapter 2 (Section 2.2.1). The seed-
mediated growth method consists of two steps, i) symmetry breaking of Au which 
involves nucleation, growth and the development of facets and ii) binding of the 
surfactant (i.e CTAB) to the facets as depicted in Figure 3.2. Briefly, during the first 
step, gold salt (HAuCl4) is reduced using a strong reducing agent, such as sodium 
borohydride (NaBH4) to form faceted AuNSs with an average diameter of 3nm (Figure 
3.2). The final step involves placing the AuNS seeds in HAuCl4 solution and a mild 
reducing agent (ascorbic acid) to grow into AuNRs. The CTAB surfactant (capping 
Figure 3.1: Schematic of the AuNP design. AGK = AuNRs functionalised with both targeting (AHP) and 
therapeutic (D(KLAKLAK)2) peptides, G = AuNRs before functionalization, GP = pegylated AuNRs, GK = 
AuNRs functionalised with the D(KLAKLAK)2 peptide only and AG = AuNRs functionalised with the AHP 
peptide only.  
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agent) and Ag (shape directing agent) selectively adsorb on the side facets of the 
AuNRs (Abtahi, 2013). CTAB forms a micellar bi-layer around side facets of AuNRs 
(Nikoobakht and El-Sayed, 2001). This bilayer formation blocks and slows down the 
growth of side facets in the transverse axis while tip facets are not covered and can 
grow rapidly in the longitudinal axis (Abtahi, 2013).  
 
 
 
  
 
 
 
 
3.2.2. Tuning of AuNR size  
 
A fascinating feature of AuNRs is that their plasmonic properties can be tailored by 
synthetically tuning their size. Of all parameters involved in the synthesis process, the 
seed-to-Au (III) ions ratio in the growth solution has the most significant effect on the 
size of the AuNRs (Sau and Murphy, 2004 & Jia et al., 2015). Since the ultimate goal of 
this study is to produce AuNRs that can be used for PTT, it was crucial to synthesise 
AuNRs that can efficiently absorb NIR light. Previous studies have shown that AuNRs 
become absorption-dominant if their diameters are less than 10nm (Ni et al., 2008 & 
Figure 3.2: AuNR formation using the seed-mediated technique. Seeds of Face Centre Cubic (FCC) 
metals such as Au, undergo a process of nucleation, growth and develop facets before forming rod-
shapes. Once the basic structure is formed, CTAB and ascorbic acid bind to the surface, enabling AuNR 
stability and growth along the longitudinal axis (Murphy et al., 2005). 
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Chen et al., 2010). Jia et al. (2015) demonstrated the size of the synthesised AuNRs 
usually decreases as the seed concentration is increased at a given concentration of 
Au (III) ions. This is because of a decreased number of available Au (III) ions per seed 
particle. 
 
 
3.2.2.1. Characterisation of AuNRs 
 
3.2.2.1.1. Optical properties of AuNRs 
 
UV-Vis absorbance spectroscopy is one of the most widely used techniques for the 
characterization of AuNPs. In this technique light with different wavelengths is passed 
through the sample and its incident and transmitted intensities are measured 
(Mehta, 2012). For the purpose of this study, the UV-Vis absorbance of AuNRs 
produced at different seed-to-Au (III) ion ratios were studied at an incident 
wavelength spectrum of 200 to 1100nm. The UV-Vis absorption spectrum of a typical 
AuNR suspension shows two absorption peaks whereas only one peak is generated 
for a suspension for AuNS (Haiss et al., 2007). The first peak (at the lower 
wavelength) is called the transverse plasmon wavelength (λT) and the second peak (at 
the higher wavelength) is called the longitudinal plasmon wavelength (λL). The aspect 
ratio (nanorod length divided by its width) is a function of the λL peak of AuNRs. 
Narrow NRs, which produce the λT peak at a short wavelength and a λL peak that is 
shifted far into the NIR region of the electromagnetic spectrum will have a higher 
aspect ratio (Haiss et al., 2007). The standard aspect ratio for AuNRs is 3 to 5. AuNRs 
with a higher aspect ratio will absorb NIR more efficiently.  
 
AuNP synthesis was done at three different seed-to-Au (III) ion ratios to produce 
three different AuNR preparations (G6S4, G8S2 and G9S1) as described in Chapter 2 
(Section 2.2.1).  They are named based on GmSn, where G denotes the growth 
solution, S refers to the seed solution, m is the volume (ml) of CTAB used in preparing 
the growth solution and n is the volume (ml) of the seed solution. Figure 3.3 shows 
the normalized extinction spectra of the AuNR samples prepared with CTAB and all 
http://etd.uwc.ac.za/
62 
 
three samples clearly exhibit two plasmon resonance peaks. The three AuNR 
preparations produced a similar traverse band at 505nm, while the λL bands differed 
between the AuNR preparations. G6S4, G8S2 and G9S1 produced λL peaks at 705, 730 
and 800nm, respectively. The peak intensity of the absorbance for the λL peak (which 
was approximately 0.3units) for G6S4 AuNPs was not much different from the peak 
intensity of the absorbance for the λT peak. Conversely, the peak intensity of the 
absorbance for the λL peak for G8S2 and G9S1 was higher (0.7 and 1.12units, 
respectively) than the absorbance for the λT peak. These properties are summarised 
in Table 3.1.  
 
Figure 3.3 indicates that as the amount of seed in the growth solution is increased, 
the λL peak of the AuNR samples is gradually shortened from 800nm (G9S1) to 730nm 
(G8S2) to 705nm (G6S4). Jia et al. (2015) explained that this essentially means that 
the λL peak blue shifts (shifts to the left) as the seed amount is increased. 
Theoretically, adding more seeds to the growth solution should mean there are more 
seeds present in the system for growth, resulting in more nanorods grown. However, 
there is a limiting HAuCl4 concentration for rod growth (Sau and Murphy, 2004). Once 
all the Au (III) ions in the growth solution is depleted by ascorbic acid, the nanorod 
growth process stops. As a result, the excess seeds in the growth solution grow into 
large spheres instead of rods, causing a drastic blue shift of the λL peak (Ward et al., 
2014). The λT peak however, is insensitive to the amount of seed solution added, 
which is indicated by the consistent absorbance peak at 505nm for all three samples. 
Furthermore, the larger λL peak for G9S1, compared to the other two samples, 
suggests that the yield of AuNRs in this sample is higher as a result of complete Au 
(III) ion reduction and thus the majority of the seeds were grown into rods (Figure 
3.3). In order to confirm successful synthesis of AuNRs, their size, shape and 
uniformity, HR-TEM imaging was performed on these AuNR samples. 
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3.2.2.1.2. EDX chemical analysis 
 
Energy-dispersive X-ray (EDX) spectroscopy was performed on the AuNRs in order to 
determine elemental and chemical composition. All samples were prepared using the 
drop cast technique as described in Chapter 2 (Section 2.2.3.4). EDX relies on the 
unique atomic structure ascribed to every element, in such a way that the X-ray 
spectrum emitted for the different atomic structures, are clearly discernible from one 
element to another (Rao and Biswas, 2009). The spectrum is formed by excitation of 
electrons in the inner shell (lower energies). The excited electrons move to a higher 
energy state, subsequently creating vacant shells in the electronic structure of the 
atoms being probed. Electrons from the outer shells (higher energies) replenish the 
vacant shells; and the difference in energy between the higher and lower energy 
shells are emitted as x-rays (Rao and Biswas, 2009). Based on the EDX analysis of the 
AuNR samples, it is evident that Au was present in all three samples (Figure 3.4). In 
their paper Rodríguez-León et al. (2013) indicate that the presence of strong peaks 
for Copper (Cu) and Carbon (C) and Silicon (Si) in some samples can be attributed to 
the copper TEM grid and detector window.  
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Figure 3.3: UV-Vis spectra of AuNR samples synthesised by varying the seed-to-Au (III) ion ratio in 
the growth solution. They are named based on GmSn, where G = growth solution; S = seed solution; 
m = volume of CTAB used in preparing the growth solution and n = volume of the seed solution. The 
seed solution was incubated for 3hrs before it was added to the growth solution. The resulting 
mixture was left undisturbed overnight at 25°C, after which the colour changed from colourless to 
deep purple. 
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A B 
C 
Figure 3.4: EDX spectrum of the AuNR samples. A, B and C shows the spectrum for G6S4, G8S2 and G9S1, respectively. The individual peaks are labelled with the 
symbols for the different elements that was detected in the samples. The red arrows point to the peaks representing Au.   
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3.2.2.1.3. HR-TEM analysis 
 
High Resolution (HR)- Transmission Electron Microscopy (TEM) is the one of the most 
common characterization techniques for NPs. AuNR suspensions were loaded onto 
copper grids as described in Chapter 2 (Section 2.2.3.4) and changes in the electron 
beam due to scattering discharged by the sample were then measured. The 
interaction between the electrons and the sample, at that point, produced an image. 
The difference in contrast between the sample and the background Cu grid provides 
direct information about the NP morphology (Qi et al., 2001 & Rao and Biswas, 2009). 
TEM images contain a variety of information regarding shape and size distribution, as 
well as crystallographic structure of the NPs. The HR-TEM micrograph for the AuNR 
samples is shown in Figure 3.5. These images suggests that during synthesis, in all 
three samples, not only were there a very low yield of rod-shaped particles produced, 
but NPs with various morphologies, which includes spheres, prisms, and cubes were 
also formed. The majority of the AuNPs produced were in fact high-index-faceted Au 
nanocrystals, which according to Ming et al. (2009) can be produced when the seed 
amount is much smaller than that used for the preparation of larger AuNRs (>10nm). 
The TEM images (Figure 3.4) corroborate the UV-Vis data (Figure 3.3) which indicates 
that a blue shift of the λL peak from the NIR region (700-1100nm) to the visible region 
(200-500nm) occurs when the seed solution is increased, resulting in a decrease in 
rod formation. The blue shift of the λL peaks of the G8S2 and G6S4 samples closer to 
the visible region indicates the presence of NPs with various morphologies (Figure 
3.3). In addition, the TEM images confirm that the higher absorbance peak of the 
G9S1 sample observed in the UV-Vis data is due to a significantly higher yield of 
AuNPs in the G9S1 sample compared to G8S2 and G6S4. Furthermore, even though 
various morphologies of NPs were present in the G9S1 sample, there was a significant 
red shift of the λL peak towards the NIR region, indicating that there was an increase 
in the abundance of rods in the G9S1 sample (Figure 3.3 and 3.4). 
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Figure 3.5: HR-TEM images of the AuNR samples. A, B and C represents G6S4, G8S2 and G9S1 NPs respectively, while i, ii and iii shows images of the samples taken at 
magnifications 50, 10 and 2nm resolution, respectively.  
  
i ii iii 
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3.2.3. Purification of AuNR from G9S1 sample 
 
3.2.3.1. Optical properties of the separated AuNPs 
 
During AuNR synthesis, it is common for other shapes of AuNPs such as nanospheres, 
nanocubes, nanoprisms and nanocrystals to form (Xiong et al., 2011), which is clearly 
visible in Figure 3.5. Thus there was a need to separate the AuNPs based on their 
shapes. Previous studies employed centrifugation for separation of AuNR from AuNPs 
with other shapes (Ahmad et al., 2014; Scaletti et al. 2014; Robertson et al., 2016 & 
Boksebeld et al., 2017). This separation technique is based on the differential 
sedimentation rates of NP with different shapes and sizes (Xiong et al., 2011).  
 
Following a method described by Scaletti et al. (2014), a differential centrifugation 
technique was used to successfully separate AuNRs from AuNPs with other shapes. 
The G9S1 sample was centrifuged as described in Chapter 2 (Section 2.2.1.2.) to 
produce a pellet and a supernatant. Figure 3.6.A shows UV-Vis spectra of AuNPs in 
the supernatant fraction, while Figure 3.6.B shows the UV-Vis spectra of AuNPs in the 
pellet fraction. The UV-Vis spectrum of the supernatant showed two defined peaks, 
one in the visible region (200-500nm) and one in the NIR region (700-1100nm), which 
is similar to the spectrum obtained for the G9S1 sample (before differential 
centrifugation). This is a clear indication of the presence of AuNRs.  The UV-Vis 
spectrum generated for the pellet was less defined with a high absorbance in the NIR 
region of the spectrum. However, this spectrum is not indicative of AuNRs, suggesting 
that the AuNR were absent from the pellet. 
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Figure 3.6: UV-Vis spectra of the fractions of AuNP produced after differential centrifugation of G9S1 sample. A shows the UV-VIS spectrum of the supernatant, 
while B shows the spectrum of the pellet.  
-0,1
0,1
0,3
0,5
0,7
0,9
1,1
1,3
1,5
400 500 600 700 800 900 1000
A
b
so
rb
an
ce
Wavelength (nm)
A B 
0
0,1
0,2
0,3
0,4
400 500 600 700 800 900 1000
A
b
so
rb
an
ce
Wavelength (nm)
http://etd.uwc.ac.za/
69 
 
3.2.3.2. EDX and HR-TEM analysis of the two NP fractions generated by 
centrifugation 
 
To confirm that the AuNRs was successfully separated from AuNPs with other shapes, 
the two fractions (the pellet and supernatant) were subjected to HR-TEM and EDX 
analysis. The EDX spectra (Figures 3.7) suggest that Au is present in both the 
supernatant and the pellet suspensions. However the spectra for the two samples 
were very different, suggesting that the composition of the two suspensions may also 
differ. The TEM micrographs (Figures 3.8) show that the supernatant contains mostly 
the AuNRs (with minimal sphere production), while the pellet contains a mixture of 
AuNRs and AuNPs with various morphologies. The TEM images substantiate the UV-
Vis analysis (Figure 3.6) and confirm that the supernatant contains the AuNRs. Based 
on the TEM images, the length of the majority of the AuNRs present in the 
supernatant fraction was 21-25nm and the diameter was 6-8nm, suggesting an 
aspect ratio of 3 to 3.5. Although the diameter of 80% of the AuNR was 6-8nm, a 
significant variation in the length of the AuNR was observed for AuNRs in the 
supernatant. Approximately 85% of the AuNRs in the supernatant can be divided into 
four groups based on their lengths (10-15, 16-20, 21-25 and 26-30nm) (Figure 3.9). 
Approximately 28%, which is the majority of the AuNRs, had a length of 21-25nm, 
24% had a length of 16-20nm, 17% had a length of 26-30nm and another 17% had a 
length of 10-15nm. The properties are summarised in Table 3.1. The study by Jia et al. 
(2015) used a seed-to-Au (III) ions ratio similar to the ratio used to synthesise G9S1 
AuNRs. Jia et al. (2015) produced AuNRs with a length of approximately 45nm, a 
diameter of 9nm and an aspect ratio of 5. In the current study, temperature was not 
efficiently controlled which may explain why the characteristics of the AuNR 
produced in this study was different from the AuNRs produced by Jia et al. (2015). 
Only the supernatant fraction of the G9S1 was used in subsequent experiments.  
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 Figure 3.7: EDX spectra of the two fractions generated by centrifugation. A and B shows the spectrum of the supernatant and pellet, respectively. The individual 
peaks are labelled with the symbols for the different elements that was detected in the samples. The red arrows point to the peaks representing Au.   
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Figure 3.8: HR-TEM images of the two AuNP fractions generated from the G9S1 sample.  A and B represents the supernatant and pellet respectively, while i and ii 
shows images of the supernatant and pellet at magnifications 50 and 10nm resolution, respectively.  
i ii 
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Figure 3.9: AuNR size distribution of the supernatant fraction of G9S1 AuNR. The A) length and B) diameter of each AuNR was determined using ImageJ software. 
The number of NPs analysed (N) = 75. 
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AuNR parameters 
AuNR preparations 
G6S4 G8S2 G9S1 
λL (nm) 705 730 800 
λT (nm) 505 505 505 
Peak intensity (units) 0.3 0.7  1.12 
Diameter (nm) _ _ 6 - 8 
Length (nm) _ _ 21 - 25 
Aspect ratio _ _ 3 - 3.5 
Number yield (%) _ _ 85 
 
 
 
 
 
 
3.2.4. Pegylation of the AuNRs 
  
CTAB is a cationic surfactant that plays a key role in the growth of the AuNRs. It 
simultaneously serves as a template for growth, while after synthesis it prevents 
aggregation of the NRs. CTAB inhibits aggregation by forming a bilayer micelle around 
AuNRs (Nikoobakht and El-Sayed, 2001). The positive charge of the bilayer results in 
reclusive forces between the AuNRs, preventing the AuNR from aggregating, which 
cause the AuNRs to stay in solution.  However, there are two main problems 
regarding CTAB stabilization of AuNRs. The first is that CTAB physisorbs on Au, i.e. 
there is no strong chemical interaction between CTAB and the Au surface (Abtahi, 
2013). Therefore, physisorbed CTAB on the surface is always in equilibrium with 
excess CTAB in the solution. If the CTAB in solution decreases, then CTAB will desorb 
from the AuNRs, which can result in the aggregation of AuNRs. The second problem is 
that the excess CTAB in solution is cytotoxic. Thus, using CTAB coated AuNRs in 
equilibrium with CTAB solution for medical applications could be problematic. 
Therefore, many researchers have attempted to replace CTAB with more 
biocompatible coatings (Liu et al., 2015 & Tebbe et al., 2015). In this study, CTAB was 
replaced with dH2O before the AuNRs were functionalised with PEG and peptides as 
 
Table 3.1: Plasmonic properties, sizes, and number yields of the AuNR samples. 
 
λL = Longitudinal plasmon wavelength (Figure 3.3); λT = Transverse plasmon wavelength (Figure 3.3); 
Peak intensity = The peak intensity of the longitudinal plasmon wavelength (Figure 3.3); Diameter = 
Diameter of the majority of the AuNRs (Figure 3.9); Length = Length of the majority of the AuNRs 
(Figure 3.9); Aspect ratio refers to the ratio of the length to the diameter; Number yield refers to the 
percentage of the number of AuNRs in the total number of NPs in the supernatant as determined by 
ImageJ; - = Data was not analysed.  
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described in Chapter 2 (Section 2.2.1.2).  Once CTAB was replaced the AuNRs were 
denoted as the G sample (Figure 3.1), which was used in subsequent experiments. 
 
Sosibo et al. (2015) demonstrated pegylation of AuNSs using thiolated PEG (SH-PEG-
OH and SH-PEG-Biotin). The authors report that the use of SH-PEG-OH only to 
stabilize AuNSs was not successful as the NPs agglomerated within a short period of 
time (Sosibo et al., 2015). To solve this problem, the stabilization was achieved by 
using the two PEG molecules, SH-PEG-OH and SH-PEG-Biotin. SH-PEG-OH was chosen 
because of its versatility with regards to solubility and biological compatibility and SH-
PEG-Biotin was employed to facilitate biotin-streptavidin conjugation of streptavidin 
tagged peptides. The same strategy was employed in this study to convert AuNRs (G) 
to pegylated AuNRs to produce GP. A mixture of SH-PEG-Biotin and SH-PEG-OH 
(mixed at a 1:10 ratio) was used to pegylate the AuNRs (G) as described in Chapter 2 
(Section 2.2.2.) to produce pegylated AuNRs (GP).  Following pegulation with a 
mixture of SH-PEG-Biotin and SH-PEG-OH, the AuNRs (G) were again analysed by UV-
Vis spectroscopy. Figure 3.10A shows the UV-vis analysis of AuNRs before and after 
pegylation. Figure 3.10A shows that in the presence of PEG the UV-vis of AuNRs (GP) 
is red-shifted from 785nm to 800nm. This shift is the result of an increase in the local 
refractive index at the AuNR surface, which suggests that PEG were successfully 
conjugated to the AuNP surface. For NPs with uneven shapes such as AuNRs this local 
refractive index change is more profound due to a further enhancement of the 
electromagnetic field at points of "unevenness" at the particle surface (Yang et al., 
2005). HR-TEM analysis of the pegylated AuNRs (GP) shows rod-shaped NPs that are 
well dispersed and not aggregating (Figure 3.10B).  
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Figure 3.10: UV-Vis Spectra and HR-TEM images of pegylated AuNRs (GP). A respresents the UV-Vis and B respresents the HR-TEM images of the NPs, at a 
magnification of 20nm resolution.  
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3.2.5. Evaluating the stability of the pegylated AuNRs (GP) 
 
It is important that AuNPs, used in biological applications, retain their stability in 
biological environments. One way to test if AuNPs will be stable in biological 
environments is to place NPs for extended periods in buffers that simulate various 
biological conditions (Chanda et al., 2011). In this study, the pegylated AuNRs were 
incubated in six different buffer solutions (dH2O, 0.5% Bovine Serum Albumin (BSA), 
1X PBS, 10% FBS, non-complete DMEM media and complete DMEM media) as 
described in Chapter 2 (Section 2.2.3.2). The stability of AuNRs in these buffers was 
monitored by recording changes in the UV-Vis spectra over time (Figure 3.11). The 
AuNRs demonstrated excellent stability in dH2O, BSA and FBS, by retaining their SPR 
(Figure 3.11).  
 
On the other hand the AuNRs did not show a similar stability upon incubation with 
PBS and media (both non-complete and complete) as indicated by significant changes 
in their respective UV-Vis spectra as shown in Figure 3.11. There is a blue shift in the 
SPR, which could be due to NP aggregation caused by the interaction of the AuNR 
with constituents of the media and PBS. Stability of NP suspensions is usually affected 
by the molar concentration and ionic strength of NaCl and destabilizing counterions 
such as Ca2+ and Mg2+ present in DMEM and PBS which bind to the surface of the NPs 
and prevent their cellular up take (Maiorano et al., 2010). Studies show that un-
functionalised NP suspensions are very unstable in biological systems and further 
(steric) stabilization with molecules such as peptides are usually necessary to prevent 
binding of ions and thereby increase bioavailability (Maiorano et al., 2010 & Pavlin 
and Bregar, 2012). Furthermore, a negative absorbance can be observed when NPs 
were incubated in DMEM (complete and incomplete) resulting in a downward peak 
at ~550nm. DMEM contains phenol red which absorbs at a wavelength of ~560nm 
(Xu et al., 2006). Thus a possible explanation for the negative absorbance could be 
attributable to the competition between the AuNPs and phenol red for the 
absorbance of light at 550nm. The interference of phenol red could significantly 
affect the cell viability readings of the NP cytotoxicity assays, as all the bioassays were 
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performed in phenol-containing media. Replacing the phenol-containing DMEM with 
phenol-free DMEM would eliminate the ambiguity of the stability test of the NPs. 
Thus, a comparative study between the stability of peptide-functionalised NPs in 
phenol-containing DMEM and in phenol-free DMEM should be done. Furthermore, 
there is a decrease in the intensities of the maximum absorbance of the NPs over 
time in all buffers. The reduction could be attributed to NP precipitation over time, 
due to the removal of NPs at each time point.   
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Figure 3.11:  Changes in UV-Vis spectra of Pegylated AuNRs (GP) over a 24hr period in different buffers. GP was incubated in dH
2
O; 1X PBS; 0.5% BSA; 10% FBS; non-
complete DMEM media and Complete DMEM media 
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3.2.6. Functionalization of AuNRs (GP) with peptides to synthesise AGK, 
GK and AG.  
 
3.2.6.1.  Characterisation of AuNRs that was functionalised with 
peptides by UV-Vis 
 
The pegylated AuNRs (GP) were bi-functionalised by conjugating the targeting (AHP) 
peptide and therapeutic D(KLAKLAK)2 peptide to the NP through ligand exchange as 
described in Chapter 2 (Section 2.2.2). Briefly, PEG-OH, PEG-Biotin and the 
D(KLAKLAK)2 peptide all contain a thiol (SH) group to facilitate conjugation to the 
AuNR surface. The three molecules were added simultaneously to the AuNR 
suspension to form GK (pegylated AuNR + D(KLAKLAK)2). The biotinylated AHP which 
contained a streptavidin tag to facilitate binding of the peptide to PEG-Biotin was 
added to GP to form AG (pegylated AuNR + AHP). Similarly the biotinylated AHP was 
added to GK to form AGK (pegylated AuNR + AHP + D(KLAKLAK)2). AG and GK served 
as control NPs as AG are expected to target cells but have no therapeutic effect and 
GK are expected to not exert its therapeutic effects on cells as it is unable to bind to 
the target of interest.  
 
Figure 3.12 shows the UV-Vis analysis of G, GP, GK, AG and AGK. All five samples 
show a λT peak at 495nm. The λL peaks for G, GP, GK, AG and AGK was 794nm, 
804nm, 806nm, 808nm and 812nm respectively. This suggests that the λL peaks for 
AuNRs that were functionalised (GP, GK, AG and AGK) were slightly redshifted. As 
explained previously, this is an indication of changes on the surface of AuNPs and 
may also indicate successful functionalisation. When comparing the NPs 
functionalised with peptides (GK, AG and AGK) to the pegylated NP (GP), the redshift 
was more pronounced for AGK. This may be due to the fact that the surface changes 
on AGK were more substantial, since it is the only AuNR that was conjugated with 
two different peptides. It can also be observed that there was a decrease in the peak 
intensities of the λL peaks of AG and AGK compared to G, GP and GK. This may be 
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attributed to the additional centrifugation steps during synthesis of AG and AGK 
resulting in the loss of NPs and therefore intensity.  
 
 
 
 
 
 
 
 
  
3.2.6.2. Characterisation of surface charge of AuNRs  
 
The zeta(ζ)-potential of a NP solution is a measure of the surface charge of the NP. ζ-
potential determines the behaviour of NPs in solution. It provides information about 
NP stability in solution (Leroy et al., 2011). NPs with higher ζ-potential exhibit 
increased stability due to a larger electrostatic repulsion between NPs. NPs with a ζ-
potential between −10 and +10mV are considered to be neutral (Clogston and Patri, 
2011). NPs with a ζ-potential greater than +30mV are strongly cationic, while NPs 
with a ζ-potential less than −30mV are strongly anionic. These values can be used to 
predict how readily the NPs will aggregate in solution. NPs with ζ-potential values 
greater than +30 mV, but less than -30mV, are highly stable and are less prone to 
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Figure 3.12: UV-vis spectra of AuNRs functionalised with peptides. The UV-Vis spectra of G, GP, GK, 
AG and AGK is shown. G = AuNRs before functionalisation, GP = pegylated AuNRs, GK = AuNRs 
functionalised with the D(KLAKLAK)2 peptide only; AG = AuNRs functionalised with the AHP peptide 
only and AGK = AuNRs functionalised with both AHP and D(KLAKLAK)2 peptides. 
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aggregation, while NPs with lower ζ-potential values closer to zero can easily 
flocculate when dispersed in a solution (Clogston and Patri, 2011).  
 
The ζ-potential of G, GP, GK, AG and AGK was determined using a Malvern Zetasizer 
Nano ZS as described in Chapter 2 (Section 2.2.3.3.) and is shown in Table 3.2. The ζ-
potential of G, GP, GK, AG and AGK was determined to be -0.224, + 19.52, +16.13, 
+7.73 and +4.51mV, respectively. This implies that pegylation and the conjugation of 
peptides to G resulted in a significant increase of the surface charge of the AuNRs. 
The molecules attached on the AuNRs increased their ζ-potential from neutral in G to 
a more cationic charge when GK, AG and AGK was produced. The changes in the 
charge are attributable to molecules attached to the AuNP surface and indicate 
modification of the AuNP surfaces. AuNPs with a large negative or positive ζ-potential 
values will repel each other in suspension and there will be no aggregation of the 
NPs. AuNPs with a more neutral ζ-potential will easily flocculate since the force 
between them is not strong enough to cause repulsion. Based on the values and 
charges obtained, G is highly unstable and that in comparison, GK, AG and AGK may 
be more stable.  
 
 
 
 
 
 
 
 
 
 
 
 
  
AuNR Conjugates Zeta Potential (mV) 
G -0.224 
GP +19.52 
GK +16.13 
AG +7.73 
AGK +4.51 
G = AuNRs before functionalisation, GP = pegylated AuNRs, GK = AuNRs functionalised with the 
D(KLAKLAK)2 peptide only; AG = AuNRs functionalised with the AHP peptide only and AGK = AuNRs 
functionalised with both AHP and D(KLAKLAK)2 peptides. 
 
Table 3.2: Zeta potential measurements of AuNRs. 
Table 3.2: Zeta potential measurements of AuNRs. 
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3.2.6.3. HR-TEM analysis of functionalised AuNRs 
 
The size distribution, quality and morphology (shape) of the peptide-conjugated 
AuNRs were characterized by HR-TEM analysis. Representative TEM micrographs of 
the different AuNRs are shown in Figure 3.13. The yield of rod-shaped NPs were high, 
with a few spheres and squares formed during the synthesis of GK which is 
unavoidable (Figure 3.13). The variation in brightness of the NRs are attributed to 
diffraction contrast within the specimen. Diffraction contrast is the variation in 
intensity of diffraction (bending of waves around obstacles) across the sample (Fultz 
and Howe, 2012).  When comparing the functionalised AuNRs (GP, GK, AG and AGK) 
to unfunctionalised AuNRs (G), the functionalised NRs are more dispersed in solution, 
while G appears to be clumping together due to aggregation. Furthermore, AG and 
AGK had a high yield even though the peak intensities were lower than the other NPs 
(Figure 3.12). A possible reason for this is that the AG and AGK suspensions were 
more concentrated when subjecting the samples to TEM analysis compared to UV-Vis 
analysis. Importantly, the functionalised AuNR dispersions showed no signs of 
aggregation following functionalisation. 
Figure 3.13: HR-TEM images of AuNRs functionalised with KLAK and AHP peptides. The HR-TEM 
images represents G, GP, GK, AG and AGK taken at a magnification of 10nm resolution. G = AuNRs 
before functionalisation, GP = pegylated AuNRs, GK = AuNRs functionalised with the D(KLAKLAK)2 
peptide only; AG = AuNRs functionalised with the AHP peptide only and AGK = AuNRs functionalised 
with both AHP and D(KLAKLAK)2 peptides. 
 
G GP 
GK AG AGK 
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3.3. Conclusion 
 
The aim of this chapter was to synthesise AuNR conjugates for application in PTT. 
AuNRs were synthesised at three different seed-to-Au (III) ion ratios to produce three 
different AuNR preparations (G6S4, G8S2 and G9S1) in order to identify the ideal 
ratio for the synthesis of <10nm AuNRs. UV-Vis analysis showed that the G9S1 
preparation had the longest λL peak compared to the other preparations, suggesting 
it would absorb NIR more efficiently. It also delivered a higher yield of AuNRs as 
determined by HR-TEM. Thus the G9S1 preparation was used in subsequent 
experiments. A differential centrifugation technique was used to successfully 
separate the AuNRs from AuNPs with other shapes. The length of the majority of the 
AuNRs was 21-25nm and the diameter was 6-8nm. Based on these physical 
characteristics these AuNRs could be used for PTT.  
 
The AuNRs were coated with CTAB, which is known to be highly toxic. Using ligand 
exchange, CTAB was exchanged for PEG molecules, which are more biocompatible. 
The pegylated AuNRs were denoted as GP. To test the stability of GP, the NPs were 
placed in buffers that simulate various biological buffer conditions, and were found 
to be stable in dH2O, BSA and FBS. GP was successfully bi-functionalised with the 
targeting (AHP) peptide and therapeutic peptide (D(KLAKLAK)2), denoted as AGK. 
AuNPs lacking AHP (GK) and D(KLAKLAK)2 (AG) were also synthesised to serve as 
controls. UV-Vis analysis showed shifts in the λL peaks upon conjugation of the 
peptides, suggesting successful modification of the AuNR surface. This was further 
confirmed by ζ-potential measurements obtained for the AuNRs. HR-TEM analysis 
showed that the functionalised AuNR conjugates were well dispersed in solution and 
showed no signs of aggregation following functionalisation. In Chapter 4, the toxicity of 
the functionalised AuNRs will be evaluated.  
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Chapter Four: Investigation of the therapeutic and photothermal 
effects of AHP functionalised gold nanorods 
 
4.1. Introduction  
 
The development of nanotechnology-based therapy has potential for the treatment 
of chronic diseases such as obesity and cancer. The nanotherapeutics can be directly 
targeted to disease-associated markers and confine its therapeutic activities to the 
target cells only. The use of bi-functionalised nanoparticles with both targeting and 
therapeutic drugs could greatly enhance the specificity and sensitivity of the therapy. 
Nanotechnology-enabled targeted therapy could facilitate the development of 
precision medicine and diagnostics systems that can specifically identify and/or 
eradicate diseased cells with minimal effects to healthy tissues (Byrne et al., 2008).  
 
A vast number of experimental bi-functionalised nanotherapies has been described in 
the literature (Palanca-Wessels et al., 2016 & Ding et al., 2017) and several 
nanodrugs are currently undergoing clinical trials for targeted treatment of cancer 
(Tabernero et al., 2013; Zhou et al., 2016 & Rudin et al., 2017). Of interest to this 
study, is therapeutics using AuNP formulations as drug delivery vehicles in 
photothermal therapy (PTT). As discussed previously (Chapter 1, Section 1.8.3.3), NPs 
that can effectively convert absorbed Near Infrared (NIR) light into heat are able to 
eliminate cancer cells (Pattani et al., 2015). Several studies have shown the great 
promise PTT holds for cancer treatment through the use of AuNRs (Tsai et al., 2013; 
Mooney et al., 2014 & Abadeer and Murphy, 2016). Changing the shape and 
composition of the NP to rod-shaped can shift the surface plasmon absorption of the 
NPs into the NIR transmission window and trigger its PTT activities (Chen et al., 2007 
& Wiley et al., 2007). The goal in this chapter was to examine the effects of the AuNR 
conjugates on PHB-expressing cell lines in an attempt to improve the therapeutic 
effect of D(KLAKLAK)2 by PTT. The study by Sibuyi et al. (2017) demonstrated that 
PHB-targeted AuNSs could induce apoptosis in PHB-expressing cells, the colon cancer 
cell line, Caco-2 cells. The targeting peptide, AHP, facilitated the uptake of the AuNSs 
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by cells that express the PHB receptor on their cell surface. Once bound, the AuNSs 
were internalized and the therapeutic peptide, D(KLAKLAK)2 triggered apoptosis in 
Caco-2 cells. These AuNSs were unable to trigger apoptosis in cells that did not 
express the receptor on their surface. In this Chapter, the cellular toxicity of the AuNRs 
(described in Chapter 3) was evaluated.  
 
 
4.2.  Results and Discussion  
 
4.2.1. Evaluating PHB expression in human cell cultures 
 
The application of the targeted AuNRs produced in this study was to selectively bind 
to the PHB receptor, which is not only expressed by vascular endothelial cells of the 
WAT of obese subjects (Zheng et al., 2013) but also on the surface of some cancer 
cells as well (Jemal et al., 2011; Siegel et al., 2013; Torre et al., 2015 & Sibuyi et al., 
2017). The objective of the work in this section of Chapter 4 was to assess expression 
and localization of PHB protein in selected human cancerous and non-cancerous cell 
lines.  
 
A panel of cancer cell lines (listed in Table 2.5) were cultured to at least 70% 
confluency. PHB expression in these cells was investigated by immunocytochemistry 
(ICC) using a PHB polyclonal antibody as described in Chapter 2 (Section 2.2.5). 
Antibody binding was visualised by chromogenic staining using DAB (3,3'-
diaminobenzidine) [Figure 4.1] and fluorescence staining using an anti-PHB Alexa 
Fluor-488 secondary antibody (Figure 4.2). Chromogenic staining was visualised using 
light microscopy and fluorescence staining was detected using fluorescence confocal 
microscopy.  
 
The principle of chromogenic staining using DAB involves the oxidation of DAB by 
hydrogen peroxide in a reaction that is catalysed by horseradish peroxidase (HRP), 
which is why a HRP-conjugated secondary antibody was used to detect the PHB 
primary antibody as described in Chapter 2 (Section 2.2.5.1). The oxidation of DAB 
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produces a brown, alcohol-insoluble precipitate at the site of enzymatic activity 
(Gustashaw et al., 2010). Counterstaining with haematoxylin maintains morphological 
detail of the surrounding tissue intact and allows visualization of the protein of 
interest (O'hurley et al., 2014).  
 
Figure 4.1 shows the results of ICC using DAB. Three cancer cell lines (Caco-2, PC-3 
and U-87) show the presence of brown staining in the cells, suggesting high 
expression levels of PHB in these cell lines, while A549, CaOv-3, Caski, H157, Hek-293, 
Hep-G2, LnCap, MCF-7 and SKOV-3 do not express PHB. Previous studies have 
reported that Caco-2 cells express PHB on the cell surface (Nijtmans et al., 2000; 
Sharma and Qadri, 2004; Thovhogi et al., 2015 & Sibuyi et al., 2017). However, the 
expression of PHB in PC-3 and U87 has not been as extensively reported.  
 
The intensity of the brown stain appears to differ between the three cell lines, with 
the intensity in Caco-2 cells being more intense than in PC-3 and U-87 cells. This may 
suggest that the expression levels of PHB are higher in Caco-2 cells. In general, it 
appears that PHB is not expressed in the nuclei of these cells. However since ICC was 
done using light microscopy and since there appear to be some traces of brown 
staining in the nuclei of PC-3 cells (Figure 4.1), it is still possible that PHB is expressed 
at low levels in the nucleus. Moreover, a study by Gamble et al. (2007) reported that 
the cells express PHB in the mitochondria and nucleus. The same study also reported 
PHB expression in the mitochondria and nucleus of LnCaP and MCF-7 cell lines 
(Gamble et al., 2007).  However, the current study contradicts this finding since 
brown staining was not present in LnCaP and MCF-7 cells, suggesting that these cells 
do not express PHB (Figure 4.1). The study by Sibuyi et al. (2017) has also 
demonstrated PHB expression in MCF-7 and Caco-2 cells by means of Western blot 
analysis. The study by Sibuyi et al. (2017) also shows that PHB is not expressed on the 
surface of the MCF-7 cells, but rather in the cytoplasm. It is therefore possible that 
ICC performed in the current study is only detecting PHB expression located on the 
surface of the cells and not at the intracellular location. 
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 Figure 4.1: Immunostaining of PHB expression in a panel of human cell lines. The cells were stained with the PHB antibody and hematoxylin. The dark purple stain shows 
the location of the nucleus, while the brown stain shows PHB expression. Images were taken at 40X magnification. 
U-87 
LnCap Hep-G2 Hek-293 H157 
SKOV-3 PC-3 MCF-7 
A549 Caco-2 CaOv-3 Caski 
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Cell fixation, which is used in ICC can modify the three-dimensional structure of 
antigens, which can render them undetectable by antibodies resulting in false 
negative results (Ramos-Vara et al., 2015). In addition to conformational changes, 
fixation can cause changes in the electrostatic charge of proteins, which is critical for 
the initial attraction between antigen and antibody (Ramos-Vara et al., 2015). 
Moreover, polyclonal antibodies, which can be raised in rabbits, have higher affinity 
but lower specificity than monoclonal antibodies (Ramos-Vara et al., 2015). 
Consequently, polyclonal antibodies can also produce false results due to non-specific 
binding. A false positive or additional signal can be produced if the antibody binds to 
molecules that are structurally related to the target antigen (Hewitt et al., 2014).  
 
In an attempt to confirm the immunostaining results, a second ICC technique was 
performed using confocal microscopy. It is based on immunofluorescence / darkfield 
imaging of cells against a dark background using an antibody that is chemically 
attached to a fluorochrome in order to visualize protein expression (Jordan et al., 
2002). Confocal microscopy coupled with Z-stacking is a powerful tool for tracking 
intracellular localization of proteins. Z-stacking or focus stacking is a process where 
images are taken of a sample at different focal distances, which are then combined 
into one image and as a result the final image has a much higher resolution (Edgett et 
al., 2009). This technique is ideal for co-localisation studies and was used here to 
resolve some of the ambiguous results produced in Figure 4.1; more specifically, it 
addressed the question of PHB expression in the nuclei of Caco-2, PC-3 and U-87 
cells.  
 
Caco-2, PC-3 and U-87 cells were probed with a PHB primary antibody, which was 
detected using an anti-rabbit Alexa Fluor-488 secondary antibody as described in 
Chapter 2 (Section 2.2.5.2). Figure 4.2 shows that Caco-2, PC-3 and U-87 cells 
displayed green fluorescence due to the presence of Alexa Fluor-488, which is an 
indication of the presence of PHB. This data corroborates ICC done by chromogenic 
staining in Figure 4.1. However, no fluorescence was detected in the nuclei of the 
cells, suggesting that PHB is expressed either in the cytoplasm or on the surface of 
these cells and not the nucleus. Since no concurrent staining with markers of cell 
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structure (e.g. an antibody to a transmembrane protein or an antibody to a protein 
that is only expressed in the cytosol) were used to verify the localisation of PHB, this 
study could not confirm whether PHB is expressed on the cell surface or membrane. 
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Figure 4.2: Immunoflourescence analysis of PHB expression in cancerous cell lines. The cells were 
fixed and treated with a PHB antibody, followed by Alexa Flour 488 anti-rabbit secondary antibody. 
The cells were then mounted in DAPI flouroshield and images were taken with a confocal microscope 
at 60X magnification. 
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4.2.2. Therapeutic potential of the PHB-targeted nanotherapy 
 
Targeted nanotherapies offer hope for the treatment of chronic diseases such as 
cancer due to improved specificity and efficacy. Preclinical and human trials 
conducted using such therapies provide concrete evidence of the therapeutic 
potential of regimens that may be capable of treating debilitating diseases such as 
cancer (Kumar et al., 2014).  
 
A previous study by Sibuyi et al. (2017) demonstrated that a PHB-targeted 
nanotherapy (AuNS functionalised with the AHP and D(KLAKLAK)2 peptides) were able 
to specifically eliminate Caco-2 cells, which are PHB expressing cells, through the 
activation of apoptosis (Sibuyi et al., 2017). The aim of the current study was to show 
that AuNR that are similarly functionalised with AHP and D(KLAKLAK)2 can induce 
death in PHB expressing cells through apoptosis and PTT. The expectation was that 
these NPs would therefore be more cytotoxic to the target cells (PHB expressing cells) 
than the AuNSs produced by Sibuyi et al. (2017). 
 
In this section of Chapter 4, the aim was to investigate the toxicity of the peptide 
functionalised AuNRs, AGK (which was described in Chapter 3) on Caco-2, U-87 and 
PC-3, which were shown to express PHB in Section 4.2.1. The toxicity and therapeutic 
potential of the AGK was investigated on both the cancerous (Caco-2, U-87, PC-3) and 
non-cancerous (MCF-12A) cell lines. Cell viability was monitored using the WST-1 
assay after treatment with GP, GK, AG and AGK AuNRs. Sibuyi et al. (2017) 
demonstrated that cell death induced by AHP and D(KLAKLAK)2 functionalised AuNSs 
induce apoptosis in the target cells. In this study, the APOPercentageTM assay was 
used to investigate if growth inhibition induced by GP, GK, AG and AGK AuNRs was 
due to apoptosis.  
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4.2.2.1. Effects of AuNR on cell viability: WST-1 assay 
 
Caco-2, PC-3, U-87 and MCF-12A cells were exposed for 24hrs to increasing 
concentrations of the AuNRs (GP, GK, AG and AGK). MCF-12A cells were included as a 
non-cancerous control cell line. Cell viability was measured using the WST-1 cell 
proliferation assay as described in Chapter 2 (Section 2.2.6.1). The assay principle 
involves the conversion of tetrazolium salt (WST-1) through the action of 
mitochondrial dehydrogenase into a yellow coloured product that is measurable by 
spectrophotometry at 440nm. The colour change is directly proportional to the 
amount of mitochondrial dehydrogenase in a sample, which is a reflection of the 
number of live cells. The interference test was performed to determine whether the 
AuNRs (at the concentrations used in this study) interferes with the WST-1 assay. This 
was done by incubating the AuNRs with the WST-1 dye reagent and measuring the 
absorbance of the sample. No interference was observed for all the AuNRs used in 
this study (data no shown). 
  
DMSO is known to be toxic to cells at high doses (Vergara et al., 2014 & Siddiqui et 
al., 2016) and was used as a positive control in the viability assays. DMSO treatment 
resulted in a significant reduction in the viability of the four cell lines (Figure 4.3). The 
viability of PC-3 cells treated with AGK AuNRs at concentrations of 200µg/ml and 
higher was significantly reduced. Although the viability of PC-3 cells was affected by 
AG AuNRs, at the highest dose of 300µg/ml, the reduction in viability appears not to 
be significant. The reduction in viability in AGK treated PC-3 cells appears to be dose 
dependent. GP, GK and AG AuNRs did not affect the viability of PC-3 cells. There was 
no significant reduction in the viability of Caco-2, U-87 and MCF-12A after exposure 
to the AuNRs (Figure 4.3). The results for Caco-2 and U-87 cells was unexpected, since 
Caco-2 and U-87 was shown to express PHB and was therefore expected to be 
susceptible to the toxic effects of AGK. Moreover, the results in Figure 4.1 suggest 
that Caco-2 cells express high levels of PHB and these cells were expected to be even 
more susceptible to the effects of AGK AuNRs than PC-3 cells. Of note, the cells were 
treated with a NR concentration range of 3-1000µg/ml, however, NR concentrations 
of >300µg/ml were severely cytotoxic to PC-3 cells. The NRs showed no toxicity 
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towards Caco-2, U-87 and MCF-12A at the same concentration range. Thus, the NP 
concentration range of 0-300µg/ml was used as it clearly depicts a dose-dependent 
loss of PC-3 cell viability.  
 
Based on the design (Figure 3.1) of the AuNRs; Caco-2, PC-3 and U-87 cells should be 
able to take up AGK and AG AuNRs, since these cells express the PHB receptor. Even 
though the expression of PHB in MCF-12A cells was not investigated in this study, it 
was expected that these cells may not express high levels of PHB, since they are non-
cancerous cells. It was also expected that AGK, but not AG AuNRs would be toxic to 
the cells, since AG AuNRs are not functionalised with the pro-apoptotic peptide, 
D(KLAKLAK)2. The response of PC-3 cells, but not Caco-2 and U-87 cells were in line 
with these expectations. Even though Sibuyi et al. (2017) showed that 50% of Caco-2 
cells are eliminated using a concentration of 0.3nM spherical AGK AuNPs, it is not 
clear why the viability of Caco-2 and U-87 cells treated with AGK AuNRs were not 
affected in the current study. It is possible that higher concentrations of the AuNRs 
are needed or that PC-3 cells do express higher levels of the PHB receptor. It is also 
possible that the different size and shape of the AuNRs may have affected the 
conjugation of the peptides onto the AuNR surface, when compared to the AuNSs 
used in the Sibuyi study. Caco-2, PC-3 and U-87 cells are cancer cells and cancer cells 
are known to have numerous genetic mutations, especially in genes involved in the 
control of cell growth and apoptosis. It is also possible that the differences in the 
responses observed in Caco-2, PC-3 and U-87 cells treated with AGK AuNRs can be 
due to different genetic mutations in these cells. I.e. it is possible that Caco-2 and U-
87 cells are more resistant to apoptosis induced by AGK AuNRs. 
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Figure 4.3: Effects of AuNR conjugates on viability of human cell cultures. The cell viability of Caco-2, PC-3, U-87 and MCF-12A cells was analysed using the WST-1 
assay. Cells were treated with increasing concentrations of AuNR conjugates for 24 hours. Results represent the average of two independent experiments performed 
in triplicate. A two-tailed, unpaired t-test was used to analyse statistical significance. * = p < 0.05 and ** = p < 0.01 significant difference compared to the untreated 
sample. 
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4.2.2.2. Cellular uptake analysis of AuNRs by ICP-OES  
 
To quantify the cellular uptake of AuNRs, elemental analysis of cell lysates (prepared 
from cells that was exposed to the AuNRs) was carried out by ICP-OES. Caco-2, PC-3 
and U-87 cells were treated for 24hrs with 200 µg/ml of GP and AGK AuNRs. After 
24hrs the cells were lysed in aqua regia and analysed for the presence of Au by ICP-
OES as described in Chapter 2 (Section 2.2.6.2). The amount of Au taken up by the 
cells were calculated and expressed as a percentage of the total amount of Au the 
cells were treated with. Figure 4.4 shows the percentage of AuNRs taken up by the 
cells, as a function of the initial amount applied. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4: Quantification of internalized AuNRs in cells by ICP-OES. The cells were incubated with 
200µg/ml of nanomaterials at 37°C for 24hrs. Cells were washed, lysed in aqua regia (3:1 hydrochloric 
acid: nitric acid) and analysed for gold concentration by ICP-OES. The percentage of AuNRs taken up by 
the cells was determined as a function of the total amount of AuNRs applied.  GP = Pegylated NPs, AGK 
= has both targeting and therapeutic peptides. A two-tailed, unpaired t-test was used to analyse 
significance. ** = p< 0.01 significant difference compared to untreated sample.  
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The three cell lines (Caco-2, PC-3 and U-87 cells) show the presence of Au, suggesting 
these cells have taken up the AuNRs. The uptake of both AuNRs (GP and AGK) in all 
cell lines was below 25%. However, U-87 was the only cell line that showed 
significant uptake of AGK AuNPs. This suggested target specific uptake of AGK AuNRs 
by U-87 cells. However Caco-2 and PC-3 cells did not take up AGK AuNRs at significant 
levels. This was unexpected since all three of these cell lines was shown to express 
PHB. Moreover, Sibuyi et al., (2017) demonstrated the targeted delivery of AGK 
AuNSs to Caco-2 cells. It is not clear why Caco-2 and PC-3 cells did not demonstrate 
targeted up take of AGK AuNRs. It is possible that the expression levels of PHB are 
higher in U-87 cells. Even though the ICC results indicate that U-87 cells have a lower 
expression level of PHB compared to PC-3 and Caco-2 cells (Figure 4.1), it is possible 
that U-87 cells express higher levels of the PHB receptor on the cell surface. Thus, the 
PHB expression should be confirmed with western blot analysis and cell surface 
expression could be confirmed with plasma membrane staining. In addition, a time-
based uptake study should be optimised as AGK could have exited the Caco-2 and PC-
3 cells before the up take study was performed. It is also possible that conjugation of 
the targeting peptide, AHP is more efficient for AuNSs compared to AuNRs, as a result 
AGK AuNSs can be delivered to Caco-2 cells more effectively. A comparative study 
between the cytotoxicity of AGK AuNSs and AuNRs on PC-3 cells should be done to 
confirm this.  
 
Interestingly, even though the uptake of AGK AuNRs appears to be very low, these 
NPs were still able to induce cell death in PC-3 cells (Figure 4.3). U-87 and Caco-2 cells 
were unaffected by AGK treatment, suggesting that the NPs were taken up by the 
cells but not at levels high enough to cause cell death. Higher concentrations of the 
AGK AuNRs are therefore required. 
 
 
4.2.3.  Investigating possible apoptotic cell death induced by AuNRs 
 
Section 4.2.2.1 demonstrated that AGK and possibly also AG AuNRs induce cell death 
in PC-3 cells. Based on the results obtained with the WST-1 assay, the AuNRs did not 
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significantly affect the viability of Caco-2 and U-87 cells. Since AGK AuNRs are 
functionalised with the pro-apoptotic peptide, D(KLAKLAK)2 it is expected that cell 
death induced by these NPs is due to the activation of apoptosis. The D(KLAKLAK)2 
peptide has pro-apoptotic activity and has been shown to induce cell death through 
apoptosis when internalized by cells (Ellerby et al., 1999). 
 
To assess the mode of growth inhibition following exposure of cells to AuNRs, the 
APOPercentageTM assay was used to determine if AGK AuNRs induced apoptosis in 
PC-3, Caco-2 and U-87 cells. It was also important to confirm using another assay that 
AGK AuNRs did not induce cell death in Caco-2 and U-87 cells. The APOPercentageTM 
assay employs the disodium salt of 3,4,5,6,-tetrachloro-2' ,4' ,5' ,7'–
tetraiodofluorescein which stains apoptotic cells purple-red. Only apoptotic cells that 
undergo the translocation of the phosphatidyl serine (PS) from the inner cell 
membrane to the outer leaflet will take up the APOPercentageTM dye (Verhoven et 
al., 1995). Apoptosis was quantified by measuring the dye incorporated by apoptotic 
cells using the BD Accuri flow cytometer as described in Chapter 2 (Section 2.2.6.3). 
Caco-2, PC-3 and U-87 cells were exposed to GP and AGK AuNRs at a concentration of 
200µg/ml for 24hrs and were thereafter stained with APOPercentageTM dye.  
 
The number of apoptotic cells after GP treatment were not significantly different 
when compared to untreated cells except in the case of Caco-2, which produced even 
less apoptotic cells than the untreated control Figure 4.5. AGK AuNRs were able to 
induce significant levels of apoptosis in PC-3 cells (70%) when compared to the 
untreated control as shown in Figure 4.5. This correlates with the results obtained for 
the WST-1 assay in which these cells were susceptible to AGK AuNRs at the same 
concentration (200µg/ml) resulting in a reduction in the viability of the cells (Figure 
4.3). The level of apoptosis in Caco-2 and U-87 cells treated with AGK AuNRs was not 
significantly higher than the untreated control. Results from this in vitro study 
showed that the targeted nanotherapy (AGK) had a more pronounced cytotoxic 
effect on PC-3 than the other AuNR-conjugates, which had negligible impact on 
cellular function at the dosage used here (Figure 4.3 and Figure 4.5). This data 
confirmed that the pro-apoptotic peptide, D(KLAKLAK)2 was responsible for the death 
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of PC-3 cells in response to AGK. Figure 4.5 also shows that the level of apoptosis in 
cells treated with DMSO, although it is higher than the untreated controls, is not 
significantly higher than the level of apoptosis in untreated controls. This may suggest 
that a higher concentration of DMSO must be used. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This study shows that the modification of the AuNR surface by chemical conjugation 
of peptides significantly influenced the interaction of the AuNRs with PC-3 cells, and 
their effects by increasing the cellular uptake and bioactivity. Similar effects have 
been reported for AuNPs in other studies where these AuNPs has been used as target 
specific delivery vehicles for anticancer therapies through the use of antibodies 
(Palanca-Wessels et al., 2016 & Rudin et al., 2017), aptamers (Hoellenriegel et al., 
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Figure 4.5: Analysis of the apoptotic effects induced by the AuNRs. Caco-2, PC-3 and U-87 cells were 
treated for 24 hrs with 200µg/ml of GP and AGK AuNRs, afterwich apoptosis was assessed by flow 
cytometry using the APOPercentageTM assay. The insert shows an example of the histogram data 
generated for AGK treated PC-3 cells. All treatments were done in triplicate and the bar graphs show 
the median percentage apoptosis cells, which was determined from the histograms. DMSO was used as 
a positive control. Untreated = negative control; DMSO = DMSO treated (XX) positive control; 
GP=Pegylated AuNRs; AGK = AuNRs with both targeting and therapeutic peptides. A two-tailed, 
unpaired t-test was used to analyse significance. * = p < 0.05 and ** = p < 0.01 significant difference 
compared to the untreated sample. 
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2014 & Liu et al., 2013) and targeting ligands (Chen et al., 2014; McGuire et al., 2014; 
Wang et al., 2016 & Ding et al., 2017). The ability of targeting agents to target 
disease-specific markers provides a viable approach to reduce the off-target effects 
and increase the drug efficacy, which means that lower dosages of the drugs can be 
used (Ruoslahti et al., 2010). NP-based delivery systems have been extensively 
studied in cancer and several preclinical studies and have since progressed 
successfully to human trials, with a variety of drug candidates still in the pipeline. The 
recently evaluated human clinical trials for targeted nanotherapies provide evidence 
that these systems can provide improved and better treatment strategies 
(ClinicalTrials.gov numbers; NCT00356980, NCT00436410 and, NCT00848042).  
 
 
4.2.4. Photothermal potential of AuNRs 
 
Sibuyi et al. (2017) proved, using Caco-2 cells as a model, that PHB targeted AuNSs 
can trigger apoptosis in PHB expressing cells. It was demonstrated in Section 4.2.3 
that AuNRs (i.e. AGK) that are similarly functionalised are able to induce apoptosis in 
PC-3 cells through the activation of apoptosis via the D(KLAKLAK)2 peptide. These 
AuNRs were not able to activate apoptosis in Caco-2 cells. The aim of this section of 
the study was to investigate if AuNRs that are similarly functionalised with peptides 
can also activate cell death through PTT. Since AuNRs (AGK and AG AuNRs) that have 
been functionalised with the targeting peptide (AHP) was not toxic to Caco-2 cells, 
these cells were selected as the model cell line to study photothermal activated cell 
death. 
 
Caco-2 cells were exposed for 30min to 500µg/ml of AG AuNRs as described in 
Chapter 2 (Section 2.2.6.4). These AuNRs were pegylated and functionalised with the 
PHB targeting peptide, AHP. Thereafter, untreated control cells and cells treated with 
AG were exposed to a NIR (780nm) laser for a time period of 30sec to 5min. The 
distance of the laser from the cells was set at 15cm. Morphological changes were 
assessed via light microscopy and the cell viability was measured using the WST-1 cell 
proliferation assay as described in Chapter 2 (Section 2.2.6.1).  
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4.2.4.1. Effect of Photothermal therapy on cell morphology 
 
The first and most readily noticeable effect following exposure of cells to toxic 
substances or stress is the alteration of cellular features such as shape and size 
(Häcker, 2000). 
 
Caco-2 cells grow and differentiate into monolayers characterized by elongated 
shape that resemble the small intestinal epithelium under microscopy (Herold et al., 
1994). Typical cellular features of Caco-2 cells are shown in untreated cells in Figure 
4.6. Cells treated with the laser only showed no morphological changes, at all 
exposure times tested. The shape of the cells treated with DMSO is distinctly 
different from the untreated control cells. DMSO treated cells are more spherical and 
may be in the process of detaching from the plate. Cells treated with a combination 
of laser exposure and AG (AG + Laser treatment), also do not show distinctive 
morphological changes at all exposure times, as the cell density and shape was 
similar to that of the untreated control cells (Figures 4.6). Of note, as this was a 
gateway experiment, this protocol had not yet been optimized, thus it is possible that 
the cells might not have been exposed to laser treatment for long enough, as a result 
the PTT was not successful. The distance of laser from the cells may also have been 
too far.  
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Figure 4.6:  Effect of AG Photothermal therapy on Caco-2 cells. The cells were seeded in 96 well plates and treated for 30 minutes with gold nanorods 
functionalised with the targeting peptide AHP (AG). Following uptake, cells were exposed to a laser with a peak wavelength of 780nm for a time ranging between 30 
seconds and 2 minutes. The cells were incubated for 24hrs post laser treatment and images taken with a light microscope at 10X magnification.  
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4.2.4.2. Effect of photothermal therapy on cell viability: WST-1 assay 
 
In order to thoroughly investigate whether the AuNRs produced in this study could be 
used for PTT, the viability of Caco-2 cells was assessed using the WST-1 assay. The 
experimental set-up was exactly the same as described in Section 4.2.4.1. 
 
The viability of cells treated with the laser only or with AG AuNRs only was not 
significantly different from that of untreated control cells (Figure 4.7), while the 
viability of cells treated with DMSO and cells exposed to laser treatment and co-
treated with AG AuNRs was significantly reduced. The viability of DMSO treated cells 
was reduced to ±70%. Cells exposed to laser treatment for 2 and 5min and co-treated 
with AG AuNRs were significantly reduced to 72 and 49%, respectively. Laser 
treatment of 30sec and 1min did not have an effect on cell viability. The steep decline 
in viability after 5min of treatment could be an indication that AG AuNRs are 
effectively internalized and that an exposure time of 5min or more to the NIR laser 
results in photothermal effect, resulting in the death of the cells. The WST-1 assay 
thus show that even though no morphological changes were observed in Caco-2 cells 
subjected to laser treatment for 5min and co-treated with AG AuNRs, these cells 
were indeed affected by the co-treatment which resulted in the death of the cells.  
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Figure 4.7: Effect of AG-induced photothermal therapy on Caco-2 cells. The cells were seeded in 96 well plates and treated for 30 minutes with gold nanorods 
functionalised with the targeting peptide AHP (AG). Following uptake, cells were exposed to a NIR laser with a peak emission wavelength of 780nm for time periods 
ranging between 30 secs and 5 min. The WST-1 assay was performed to assess cell viability. A two-tailed, unpaired t-test was used to analyse significance. * = p < 
0.05 and *** = p < 0.001 significant difference compared to the untreated sample. 
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4.3. Conclusion 
 
The aim of this chapter was to examine the cytotoxic effects of the AuNR conjugates 
on PHB-expressing cell lines. As the application of the targeted AuNRs is to selectively 
bind to the PHB receptor, the expression and localization of the PHB protein in 
selected human cell lines was assessed. Immunocytochemical staining confirmed the 
expression of PHB in Caco-2, PC-3 and U-87 cells.  In general, it appears that PHB is 
expressed either in the cytoplasm or on the surface of these cells.  
 
The toxicity of the AuNRs bi-functionalised with the targeting (AHP) peptide and 
therapeutic peptide (D(KLAKLAK)2) i.e. AGK was investigated on the PHB expressing 
cells. Although the three cell lines demonstrated the uptake of AGK AuNPs, U-87 was 
the only cell line that demonstrated target specific uptake of AGK AuNPs. However, 
the WST-1 assay showed that AGK was not toxic to Caco-2 and U-87 cells. PC-3 was 
the only cell line that was affected by AGK AuNRs. The results for Caco-2 and U-87 
cells were unexpected, since Caco-2 and U-87 was shown to express PHB and was 
therefore expected to be susceptible to the toxic effects of AGK AuNRs. Even though 
AGK AuNRs were taken up by PC-3 cells the uptake cannot be attributed to the 
expression levels of the PHB receptor on these cells. Therefore the toxicity in PC-3 
was likely due to PC- 3 cells being more susceptible to the toxicity of AGK at lower 
concentrations compared to Caco-2 and U-87. The APOPercentageTM assay correlates 
to the WST-1 assay as AGK had a more pronounced cytotoxic effect on PC-3 than the 
other AuNR-conjugates, confirming that the pro-apoptotic peptide, D(KLAKLAK)2 was 
responsible for the death of PC-3 cells in response to AGK. As AGK was not toxic to 
Caco-2 cells, these cells were selected as the model cell line to study PTT. Even 
though no morphological changes were observed in Caco-2 cells subjected to laser 
treatment, these cell were indeed affected by the co-treatment which resulted in the 
death of the cells.  
 
The overall aim of this study was to examine the effects of AGK on PHB-expressing 
cell lines in an attempt to improve the therapeutic effect of D(KLAKLAK)2 by PTT. 
Therefore, a shortcoming of this chapter is that PHB-expressing cells have not been 
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co-treated with AGK and laser exposure in order to determine if PTT could in fact 
enhance the therapeutic effect of D(KLAKLAK)2 on these cells. This study has however 
shown that AGK selectively targets and induces apoptosis in PC-3 cells through 
D(KLAKLAK)2 induced apoptosis. Furthermore, it has shown that AG can eliminate 
PHB-expressing cells via PTT. Therefore, even though the overall objective of this 
study has not been investigated, the findings suggest great promise that the co-
treatment of AGK and laser exposure could enhance the therapeutic effects of 
D(KLAKLAK)2.  
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Chapter five: Summary of this study 
 
5.1. General discussion  
 
Cancer is one of the leading causes of death, worldwide. It is a progressive disease, in 
that accumulative changes occur at the genetic level. Subsequently, presenting a 
disease that is complex and life-threatening (Pal and Nayak, 2010). Mortality tolls are 
estimated to reach approximately 13.1 million in 2030. These statistics suggest that 
current therapeutic strategies are not effective, highlighting the need for alternative 
therapeutic approaches (Sumer and Gao, 2008).    
 
The non-specific distribution of conventional chemotherapeutic drugs through the 
body can result in severe toxicities (Agnihotri et al., 2011). As a result the drug 
dosages must be reduced which can severely affect the efficiency of 
chemotherapeutic drugs. Overall, the objective in the treatment of cancer is to 
deliver drugs through the blood circulation directly to the diseased tissues/cells, with 
little to no damage inflicted on healthy cells (Byrne et al., 2008). In view of this, the 
therapeutic goal of chemotherapy has shifted towards targeted drug delivery 
systems, which have been successfully demonstrated using nanotechnology. 
Nanomaterials have a large surface area to size ratio, which increases their capacity 
to carry drugs or biomolecules. These features can be exploited for bio-medical 
applications by attaching drugs, bio-active molecules or targeting moieties for either 
therapeutic and/or diagnostic purposes. Several NPs have been successfully used in 
cancer treatment, of which AuNPs have been applied as drug delivery vehicles 
(Niikura et al., 2013 & Paul et al., 2014). The unique properties exhibited by AuNPs 
are attributed to their optical properties, namely, their ability to strongly scatter light 
and enhance the local electric field (Jain et al., 2007, 2008). AuNRs in particular 
possess several advantages including large absorption cross sections, tunable 
longitudinal plasmon wavelengths, high chemical stability, and efficient photothermal 
conversion ability, enabling their applications as optically active agents for various 
biomedical applications, such as photothermal therapy (PTT) [Alkilany et al., 2012; 
Mooney et al., 2014 & Park et al., 2014].  
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A study by Sibuyi et al. (2017) demonstrated that AuNSs bi-conjugated with a PHB-
targeting peptide (AHP) and a therapeutic peptide, the pro-apoptotic peptide 
D(KLAKLAK)2 are specifically taken up by cells that express the PHB (the colon cancer 
cell line Caco-2) on their surface. It was also demonstrated that the uptake of these 
AuNP resulted in the activation of apoptosis in these cells. This finding suggested that 
these AuNPs could potentially be used as a target specific therapeutic for the 
treatment of cancers where PHB was over expressed. However, if this 
nanotherapeutic was redesigned and the AuNSs were replaced with AuNRs, these 
nanoparticles could also be used as PTT. Hence the aim of the current study was to 
explore the synthesis and characterisation of AuNRs that was bi-conjugated with AHP 
and D(KLAKLAK)2. The therapeutic effect of these AuNRs was expected to be even 
higher when compared to the AuNSs reported in the Sibuyi study due to the 
synergistic effect brought about by the delivery of the pro-apoptotic peptide 
D(KLAKLAK)2 and PTT. 
 
The first objective involved the synthesis and characterization of AuNRs, the 
functionalisation of the AuNRs with the targeting peptide (AHP) and the therapeutic 
peptide (D(KLAKLAK)2). Previous studies have shown that AuNRs become absorption-
dominant if their diameters are less than 10nm (Ni et al., 2008 & Chen et al., 2010). 
Thus, it was crucial to control the size of the AuNRs in order to efficiently absorb NIR 
light. As the seed-to-Au (III) ions ratio in the growth solution has the most significant 
effect on the size of the AuNRs (Sau and Murphy, 2004 & Jia et al., 2015), three 
different seed-to-Au (III) ion ratios were used for AuNR preparations (G6S4, G8S2 and 
G9S1) in order to identify the ideal ratio for the synthesis of AuNRs with a diameter 
<10nm. UV-Vis analysis showed that the G9S1 preparation had the longest λL peak 
compared to the other preparations, suggesting it would absorb NIR more efficiently. 
EDX and HR-TEM micrographs confirmed that Au was present in the samples and that 
the G9S1 sample had the highest AuNP yield, respectively.  
 
During AuNR synthesis, it is common for other shapes of AuNPs such as nanospheres, 
nanocubes, nanoprisms and nanocrystals to form (Xiong et al., 2011), which was 
evident in the HR-TEM images (Figure 3.4). Thus there was a need to separate the 
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AuNPs based on their shapes. Previous studies employed centrifugation for 
separation of AuNR from AuNPs of different morphologies (Ahmad et al., 2014; 
Scaletti et al. 2014; Robertson et al., 2016 & Boksebeld et al., 2017). This separation 
technique is based on the differential sedimentation rates of NP with different 
shapes and sizes (Xiong et al., 2011). The UV-Vis spectrum of the supernatant showed 
two defined peaks, one in the visible region (200-500nm) and one in the NIR region 
(700-1100nm), which is similar to the spectrum obtained for the G9S1 sample (before 
differential centrifugation). This is a clear indication of the presence of AuNRs.  The 
UV-Vis spectrum generated for the pellet was much less defined, suggesting that the 
majority of AuNRs were absent from the pellet. To confirm that the AuNRs was 
successfully separated from AuNPs with other shapes, the two fractions (the pellet 
and supernatant) were subjected to HR-TEM and EDX analysis. The EDX spectra 
suggest that Au was present in both the supernatant and the pellet suspensions. The 
TEM images confirmed that the supernatant contained the majority of the AuNRs, 
while the pellet contained a mixture of other AuNP shapes. Based on the HR-TEM 
images, ImageJ determined that the length of the majority of the AuNRs present in 
the supernatant fraction was 21-25nm and the diameter was 6-8nm, suggesting an 
aspect ratio of 3 to 3.5. Although the diameter of 80% of the AuNR (which was 
denoted as G) was 6-8nm, a significant variation in the length of the AuNR was 
observed for AuNRs in the supernatant as a result of not strictly controlling the 
temperature during synthesis. Nevertheless the diameter produced was in the 
optimum range (i.e. <10nm) for PTT, according to Jia et al. (2015).  
 
While CTAB simultaneously serves as a template for growth and prevents aggregation 
of AuNRs, it is extremely cytotoxic. Thus, the CTAB needed to be removed in order for 
the NRs to be used for biological application. CTAB molecules were removed from the 
AuNR surface and replaced with PEG molecules to prevent aggregation as described 
by Sosibo et al. (2015) to produce pegylated AuNRs (GP).  Following pegylation, UV-
Vis spectroscopy showed a red shift in GP compared to G. This shift is the result of an 
increase in the local refractive index at the AuNR surface, which suggests that PEG 
were successfully conjugated to the AuNR surface. It is important that the AuNRs 
retain their stability in biological environments. To test the stability of the GP, the 
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AuNRs were placed in buffers that simulate various biological buffer conditions. UV- 
Vis analysis indicated that the AuNRs were stable in dH2O; BSA and FBS. However, the 
AuNRs were not stable in PBS and culture media.  
 
The abovementioned data proved satisfactory to proceed with peptide 
functionalisation of the AuNRs for biological application. The strategy used to 
functionalise the AuNRs (GP) with peptides was exactly the same strategy used by 
Sibuyi et al. (2017) to functionalise AuNSs. GP was bi-functionalised by conjugating 
the targeting peptide (AHP) and therapeutic peptide (D(KLAKLAK)2) to the AuNRs 
through ligand exchange. Briefly, PEG-OH, PEG-Biotin and the D(KLAKLAK)2 peptide all 
contain a thiol (SH) group to facilitate conjugation to the AuNR surface. The three 
molecules were added simultaneously to the AuNR suspension to form GK (GP + 
D(KLAKLAK)2). The biotinylated AHP which contained a streptavidin tag to facilitate 
binding of the peptide to PEG-Biotin was added to GP to form AG (GP + AHP). 
Similarly, the biotinylated AHP was added to GK to form AGK (GP + AHP + 
D(KLAKLAK)2). AG and GK served as controls. When the targeting peptide (AHP) and 
therapeutic peptide (D(KLAKLAK)2) were incorporated onto the AuNRs, there was a 
red shift in the UV-Vis peak with every peptide added, indicating successful 
functionalization of the peptides onto the AuNR surface. This was further validated 
by ζ-potential measurements, which showed drastic changes in each AuNR conjugate, 
which is attributable to the modification of the AuNR surfaces. HR-TEM analysis 
showed that the functionalised AuNR conjugates were well dispersed in solution and 
showed no signs of aggregation following functionalisation. 
 
As AuNRs were successfully synthesised, functionalised and characterised, the next 
objective was to test the ability of the AuNRs to target cancer cells and induce their 
destruction. This required appropriate cell culture models, i.e. cells that express PHB. 
The expression of PHB protein was investigated in 12 human cancer cell lines of 
which three cell lines (Caco-2, PC-3 and U-87) were found to express the protein.  
 
Caco-2, U-87 and PC-3 were treated with the AuNR conjugates and the cell viability 
was measured using the WST-1 cell proliferation assay. The WST-1 assay showed that 
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AGK was not cytotoxic to Caco-2 and U-87 cells, however, AGK reduced the viability 
of PC-3 cells in a dose dependent manner. The results for Caco-2 and U-87 cells was 
unexpected, since Caco-2 and U-87 were shown to express PHB and were therefore 
expected to be susceptible to the toxic effects of AGK. Even though AGK was taken up 
by PC-3 cells, the uptake cannot be attributed to the expression levels of the PHB 
receptor on these cells. Therefore the toxicity in PC-3 was likely due to PC-3 cells 
being more susceptible to the toxicity of AGK at lower concentrations compared to 
Caco-2 and U-87. 
 
Based on the results obtained with the WST-1 assay, it was demonstrated that AGK 
induce cell death in PC-3 cells and AGK did not significantly affect the viability of 
Caco-2 and U-87 cells. The next objective was to assess the mode of cell death 
following exposure of cells to the AuNRs. The APOPercentageTM assay was used to 
determine if AGK induced apoptosis in PC-3, Caco-2 and U-87 cells. The 
APOPercentageTM assay correlates with the WST-1 assay as AGK had a more 
pronounced cytotoxic effect on PC-3 than the other AuNR-conjugates, confirming 
that the pro-apoptotic peptide, D(KLAKLAK)2 was responsible for the death of PC-3 
cells in response to AGK treatment.  
 
The next objective of this study was to investigate if the AuNRs could activate cell 
death through PTT. Since AuNRs that have been functionalised with the targeting 
AHP peptide (AGK and AG AuNRs) was not toxic to Caco-2 cells, these cells were 
selected as the model cell line to study photothermal activated cell death. The 
cytotoxicity and change in morphology induced by AG in the presence and absence of 
laser treatment were investigated. No distinctive morphological changes were 
observed in cells treated with the laser only or with the co-treatment of the laser in 
combination with AG AuNRs at all exposure times as the cell density and shape was 
similar to untreated cells. The WST-1 assay indicated that the amount of viable cells 
following laser only treatment is similar to the untreated control, which correlates to 
the no change in morphology observed.  Interestingly, cells subjected to AG + laser 
treatment showed a decrease in viability after 2min of laser exposure with a 
significant decrease after 5min. The steep decline in viability after 5min of laser 
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treatment could be an indication that AG AuNRs were effectively internalized and 
that an exposure time of 5min or more to the NIR laser results in the photothermal 
effect, resulting in the death of the cells. The WST-1 assay thus show that even 
though no morphological changes were observed in Caco-2 cells subjected to laser 
treatment for 5min and co-treated with AG AuNRs, these cells were indeed affected 
by the co-treatment which resulted in the death of the cells. 
 
The overall aim of this study was to examine the effects of AGK on PHB-expressing 
cell lines in an attempt to improve the therapeutic effect of D(KLAKLAK)2 by PTT. 
Therefore, a shortcoming of this study is that the cells have not been subjected to AG 
+ laser treatment in order to determine if PTT could enhance the therapeutic effect 
of D(KLAKLAK)2 on these cells. This study has however shown that AGK selectively 
eliminates PC-3 cells through D(KLAKLAK)2 induced apoptosis. Furthermore, it has 
shown that AG eliminates Caco-2 cells via PTT. Therefore, even though the overall 
objective of this study has not been achieved, the findings suggest great promise that 
the co-treatment of AG + laser treatment could enhance the therapeutic effects of 
D(KLAKLAK)2.  
 
 
5.2. Conclusion  
 
The main aim of this study was to develop a nanoparticle-based targeted drug 
delivery system using peptide directed AuNRs as a delivery vehicle and to evaluate 
whether photothermal therapy could enhance the therapeutic effect. AuNRs were 
successfully synthesised and functionalized for its application in a biological 
environment. This study identified three cancer cell lines (Caco-2, PC-3 and U-87 
cells) that could be used for selective targeting of the nanotherapy. In an up take 
study, target specific up take of AGK AuNRs by U-87 cells were shown. However, this 
could not be demonstrated by Caco-2 and PC-3 cells. Higher concentrations of the 
AGK AuNRs are likely required to show selective uptake. Even through no up take was 
demonstrated, AGK AuNRs selectively eliminated PC-3 cells through D(KLAKLAK)2 
induced apoptosis, which could possibly be exploited for the treatment of prostate 
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cancer. Furthermore, AG AuNRs eliminated Caco-2 cells through PTT, which could 
possibly be exploited for the treatment of colon cancer.  
 
5.3. Future work  
 
Future directions would aim to address limitations identified in this study. The 
literature extensively demonstrates the targeting and apoptotic ability of AHP and 
D(KLAKLAK)2, respectively.  Thus the cell viability results for Caco-2 and U-87 cells was 
unexpected, since Caco-2 and U-87 were shown to express PHB and was therefore 
expected to be susceptible to the toxic effects of AGK. As PC-3 cells were susceptible 
to the toxic effect of AGK, it is possible that higher concentrations of the AuNRs are 
needed to exert toxic effects on Caco-2 and U-87. It is also possible that the different 
size and shape of the AuNRs may have affected the conjugation of the peptides onto 
the AuNR surface, when compared to the AuNSs used in the Sibuyi study. Thus 
additional techniques to confirm functionalisation should be employed such as 
Fourier-transform infrared spectroscopy (FTIR) which could identify the functional 
groups of the peptides if present (Kötting et al., 2012). Another limitation 
encountered in this study was that Imuunocytochemistry could not confirm whether 
PHB is expressed on the cell surface or membrane. Western blot analysis would 
therefore be required and the collective data would validate PHB expression.  
 
A crucial shortcoming of this study is that PHB-expressing cells have not been co-
treated with AGK + laser exposure in order to determine if PTT could enhance the 
therapeutic effect of D(KLAKLAK)2 on these cells. Thus future investigations would 
focus on subjecting Caco-2, PC-3 and U-87 cells to the AGK + laser co-treatment. In 
addition, PC-3 and U-87 cells would be subjected to AG + Laser co-treatment to 
investigate whether the same toxicity is observed as Caco-2 cells.  To corroborate the 
in vitro toxicity of the co-treatment of AG/AGK and PTT, in vivo investigations are 
necessary to clarify the mechanisms governing the toxicity. The PHB-targeted 
nanotherapy have previously shown pronounced effects on Caco-2 cells and this 
study has shown effects on PC-3 cells. Thus, the strategy requires further 
investigation to determine the effect of the PHB-targeted therapy in animal models 
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of colon cancer and prostate cancer. Since Caco-2 cells originate from a colon cancer 
patient and PC-3 cells from a prostate cancer patient (Chen et al., 2010 & O'Dwyer et 
al., 2011), PHB targeting might also be able to help in the treatment of colon cancer 
and prostate cancer. Thus, the expression of PHB in colon and prostate cancer 
patients need to be investigated as the protein has been shown to be upregulated in 
tissue samples of colon and prostate cancer patients.  
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